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RÉSUMÉ 
 
Les biomatériaux à base de collagène ont une place particulièrement importante dans le domaine 
de l’ingénierie tissulaire. Leur fonctionnalisation peut être facilement effectuée à l’aide de 
protéines chimères constituée d’une biomolécule, typiquement un facteur de croissance, fusionnée 
à un domaine de liaison au collagène. Cette fonctionnalisation peut conférer aux biomatériaux des 
propriétés mitogéniques et anti-apoptotiques, et influencer la colonisation de ce dernier par des 
cellules. De nombreuses études ont été menées en ce sens dans des domaines variés de la médecine 
régénératrice, comme la cicatrisation ou la régénération osseuse. 
Nous avons choisi d’immobiliser des facteurs de croissance étiquetés avec une hélice alpha 
(Ecoil-GF) sur un substrat de gélatine en utilisant un adaptateur moléculaire constitué du domaine 
de liaison au collagène de la fibronectine, étiqueté avec l’hélice alpha partenaire (CBD-Kcoil). Les 
hélices alpha Ecoil et Kcoil interagissent par interaction superhélice d’une manière spécifique avec 
une forte affinité, ce qui permet la formation d’un complexe entre la gélatine, l’adaptateur 
moléculaire CBD-Kcoil et le facteur de croissance Ecoil-GF. Nous avons produit et purifié le 
facteur de croissance des fibroblastes basique étiqueté avec l’hélice Ecoil (Ecoil-bFGF), et nous 
avons comparé son immobilisation avec celle du facteur de croissance épidermique, en utilisant 
l’adaptateur moléculaire CBD-Kcoil. 
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ABSTRACT 
 
Collagen-based biomaterials have attracted a lot of interest in the field of tissue engineering. Their 
functionalization can be easily performed using chimeric proteins composed of a biomolecule, 
typically a growth factor, that is fused to a collagen-binding domain. This functionalization may 
provide biomaterials with mitogenic and anti-apoptotic properties, and influence the cellular fate 
within the implant. Many studies have been conducted to this end, in various fields of regenerative 
medicine, such as wound healing and bone regeneration. 
We chose to tether coil-tagged growth factors (Ecoil-GF) on a gelatin substrate using a molecular 
adaptor consisting of the collagen-binding domain of fibronectin, fused to the complementary coil  
(CBD-Kcoil). E and K coils interacted through coiled-coil interaction in a specific manner with 
high affinity, which enabled the formation of a ternary complex between the gelatin substrate, the 
molecular adapter CBD-Kcoil and the growth factor Ecoil-GF. We have produced and purified an 
Ecoil-tagged basic fibroblast growth factor (Ecoil-bFGF), and we have compared its tethering with 
that of the epidermal growth factor, using the molecular adaptor CBD-Kcoil. 
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CHAPITRE 1 INTRODUCTION 
 
Le collagène est un matériau très populaire dans le domaine de l’ingénierie tissulaire, en 
particulier à cause de sa faible antigénicité et de son excellente biocompatibilité, ce qui en fait un 
matériau très sûr d’utilisation. Le collagène est une protéine fondamentale de la matrice 
extracellulaire, qu’on retrouve sous la forme d’une trentaine de paralogues, dont le collagène de 
type I, la protéine la plus abondante du corps humain (Figure 1.1). Il est exprimé dans la majorité 
des tissus comme la peau, les tendons, les ligaments, le cartilage, les os, les vaisseaux sanguins ou 
encore les muscles et confère une résistance mécanique aux tissus. Au vu de son importance, c’est 
une protéine extrêmement conservée au cours de l’évolution (97 % d’identité entre Homo sapiens 
et Bos taurus). Cela permet en particulier d’utiliser du collagène extrait de bœuf ou de porc pour 
fabriquer des biomatériaux qui présentent une bonne biocompatibilité chez l’homme. Un certain 
nombre d’entre eux sont déjà approuvés par les autorités de santé (la Food and Drug Administration 
et l’Agence Européenne des Médicaments). 
Figure 1.1. Structure du collagène de type I dans le corps humain 
 
Une approche prometteuse a été développée ces dernières années pour fonctionnaliser le 
collagène et lui donner, par exemple, des propriétés bio-inductives promouvant la migration, la 
prolifération, ou encore la différenciation cellulaire. Cette approche consiste à développer des 
protéines de fusion entre un domaine de liaison au collagène (issu de protéines qui se lient 
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naturellement au collagène, comme la fibronectine ou le facteur de von Willebrand) et un domaine 
bioactif (par exemple un facteur de croissance ou un domaine de liaison aux intégrines). Ces 
protéines chimères possèdent donc des propriétés de liaison au collagène en plus de leurs propriétés 
bio-inductives. De nombreuses études ont montré que ces protéines présentent un pouvoir de 
régénération beaucoup plus important que leur homologue d’origine (par exemple le facteur de 
croissance naturel), lorsqu’elles sont utilisées en adéquation avec un biomatériau à base de 
collagène. En particulier, leur biodisponibilité est augmentée car leur diffusion est limitée : ces 
protéines chimères peuvent en effet se lier au collagène endogène lorsqu’elles sont libérées du 
biomatériau. Elles ont prouvé leur utilité dans des domaines très variés de la médecine régénératrice 
(cicatrisation, régénération osseuse et neurale). 
La production de ce type de protéines de fusion (Figure 1.2.A) peut être délicate, dans la 
mesure où l’ajout d’un domaine de liaison au collagène (CBD) à un facteur de croissance peut 
altérer le repliement de ce dernier, et affecter sa bioactivité.  
L’objectif de ce travail est de développer une stratégie de fonctionnalisation du collagène basée 
d’une part sur un adaptateur moléculaire constitué du CBD de la fibronectine, fusionné à une hélice 
alpha (Kcoil), et d’autre part sur des facteurs de croissance (GF) étiquetés avec l’hélice alpha 
complémentaire (Ecoil). L’interaction superhélice E/K étant une interaction de très forte affinité, 
un complexe peut se former entre le collagène (ou la gélatine), l’adaptateur moléculaire (CBD-
Kcoil), et les facteurs de croissance (Ecoil-GF) (Figure 1.2.B). Cette approche peut théoriquement 
être appliquée à n’importe quel biomatériau obtenu à partir de collagène. 
La première partie de ce mémoire présente une revue critique de la littérature sur les protéines 
chimères contenant un CBD. En particulier, les différents CBD reportés dans la littérature sont 
comparés et caractérisés, et les avantages des protéines chimères développées dans les domaines 
de la médecine régénératrice sont mis en évidence. 
La seconde partie présente l’ensemble de la démarche de fonctionnalisation d’une surface de 
gélatine, en immobilisant des facteurs de croissance à l’aide d’un adaptateur moléculaire. Elle 
compile l’ensemble des résultats d’expériences, depuis la production et la purification des protéines 
de fusion, jusqu’à la caractérisation des interactions en jeu dans la fonctionnalisation de surface, et 
la réponse cellulaire engendrée. 
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Figure 1.2. Stratégie de fonctionnalisation du collagène à l’aide d’une seule protéine chimère (A) 
ou de deux protéines interagissant par interaction superhélice (B). 
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CHAPITRE 2 DÉMARCHE GÉNÉRALE 
 
 
 
Le cœur de ce mémoire de maîtrise est composé de deux articles. Le premier, intitulé « The design 
and use of chimeric proteins with a collagen binding domain for tissue engineering and regenerative          
medicine » a été soumis à Advanced Drug Delivery Reviews en juillet 2016. Cet article compile 
l’ensemble des domaines de liaison au collagène reportés dans la littérature et compare leurs 
propriétés biophysiques. Les connaissances développées dans cette revue permettent de mieux 
situer le CBD employé au Chapitre 3 (issu de la fibronectine) par rapport aux autres CBD. En 
particulier, elles montrent que ce dernier a été employé depuis plusieurs années, seul ou sous forme 
de protéine de fusion, qui ont été testées in vivo avec succès. Cela démontre le grand potentiel de 
ce dernier, aussi bien au niveau de ses caractéristiques biophysiques (haute affinité pour le 
collagène) que de sa biocompatibilité (étant donné qu’il est dérivé de la fibronectine humaine). 
Le second article, intitulé « The use of a chimeric collagen binding domain of fibronectin to recruit 
coil-tagged growth factors on gelatin-based biomaterial », a été soumis à Acta Biomaterialia en 
juin 2016. Ces deux journaux scientifiques ont été sélectionnés pour leur niveau d’impact dans le 
domaine étudié ; Acta Biomaterialia étant un journal de référence concernant la fonctionnalisation 
de biomatériaux dans le domaine de la médecine régénératrice tandis que Advanced Drug Delivery 
Reviews publie des revues de littérature sur les techniques émergentes dans le domaine des 
stratégies thérapeutiques.  
J’ai réalisé moi-même l’essentiel des travaux expérimentaux, avec l’aide et le soutien de Frédéric 
Murschel, Benoît Liberelle et Nesrine Riahi. J’ai aussi bénéficié de l’expérience de mon directeur 
de recherche Gregory De Crescenzo et de Frédéric Murschel concernant l’avancement général du 
projet de recherche et tout particulièrement pour la relecture des articles. 
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CHAPITRE 3 REVUE DE LITTÉRATURE 
 
 
De nombreuses techniques ont été développées pour fonctionnaliser les biomatériaux avec des 
molécules bioactives afin d’influencer la migration, la prolifération ou encore la différenciation 
cellulaire. Parmi toutes ces approches, la création de protéines de fusion comprenant un CBD est 
particulièrement prometteuse pour fonctionnaliser les biomatériaux à base de collagène. De 
nombreuses protéines, comme des facteurs de croissances, ont ainsi été fusionnées à un CBD pour 
augmenter leur biodisponibilité, avec souvent un effet très bénéfique, y compris lors d’études in 
vivo. Une revue de l’ensemble des travaux reportés dans ce domaine est présentée ici dans un 
manuscrit récemment soumis à Advanced Drug Delivery Reviews. 
 
 
 
3.1 Article 1 – The design and use of chimeric proteins containing a 
collagen binding domain for tissue engineering and regenerative 
medicine 
 
 
Cyril Addi1, Frédéric Murschel1, Gregory De Crescenzo1,* 
 
1 Department of Chemical Engineering, Biomedical Science and Technology Research Group, Bio-P2 
Research Unit, École Polytechnique de Montréal, P.O. Box 6079, succ. Centre-Ville, Montréal (QC), 
Canada H3C 3A7. 
* To whom correspondence should be addressed. E-mail address: gregory.decrescenzo@polymtl.ca 
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3.2 Abstract  
Collagen-based biomaterials are widely employed in the field of tissue engineering; they can be 
loaded with biomolecules such as growth factors to modulate the biological response of the host 
and thus improve their potential of regeneration. Recombinant chimeric growth factors fused to a 
collagen-binding domain have been reported to improve the bioavailability of these growth factors, 
especially when combined to an appropriate collagen-based biomaterial. This review first provides 
an extensive description of the various collagen-binding domains that have been characterized and 
fused to several proteins for application in the fields of tissue engineering and regenerative 
medicine. The second part of the review highlights the benefits of various collagen-binding domain 
/growth factor fusion proteins that have been designed for wound healing and bone regeneration.  
 
Keywords— growth factor; collagen-binding domain; collagen; gelatin; biofunctionalization; 
scaffold; coating; delivery 
 
3.3 Introduction 
Collagen has attracted a lot of attention in the field of tissue engineering, given its excellent 
biocompatibility, biodegradability, weak antigenicity and safety[1]. Biomaterials made of collagen 
have been commonly used in various formulations, such as hydrogels, sponges and microparticles; 
they are often made of denatured collagen (i.e. gelatin)[2]. Importantly, some of them are already 
approved by the Food and Drug Administration[3]. Moreover, the mechanical properties of 
collagen scaffolds can be tuned by cross-linking, resulting in higher tensile strength and proteolytic 
resistance[4], [5] and allowing for their use in a wider scope of applications. Also, in order to 
improve their healing potential, these biomaterials have been loaded with various biomolecules to 
be released over time, be it small molecules such as steroids, antibiotics and chemotherapy agents, 
proteins such as growth factors and antibodies, or liposomes[4]. The potential benefits of their 
loading with biomolecules are numerous as it enhances effective local concentrations of drugs, 
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hence preventing side effects due to systemic distribution and it increases drug half-life in many 
cases[6]. 
Most of the collagen-derived biomaterials that have been developed for tissue 
engineering/regenerative medicine purposes simply trap the drug in their network and release it 
over time by diffusion through the pores of the scaffold[6]. In this delivery strategy, the difficulty 
to control drug release represents a major drawback: there is generally an initial burst release which 
is not followed by a sustained release over a long period[7], [8]. In addition to the rapid decrease 
of drug concentration in time, the initial burst itself may be an issue. For example, in the case of 
Bone Morphogenetic Protein-2 (BMP2) release, it was shown to promote inflammation and 
osteoclastic activity[7]. Conversely, reducing the size of the pores in order to extend the release 
hinders nutrient transport and thus severely affects cell viability[9].  
Growth factors are frequently employed in therapeutic strategies such as bone and cartilage 
engineering[10], myocardial regeneration[11] and wound healing[12] because they can promote 
cell adhesion, migration, differentiation and proliferation. The optimal beneficial effect of these 
growth factors is determined by their spatiotemporal delivery, an essential trait that can affect cell 
fate[13]. Although no growth factor binding site has been reported in collagen yet[14], some 
growth factors, e.g. Transforming Growth Factor-β1 (TGF-β1), basic Fibroblast Growth Factor 
(bFGF) and BMP2, have a naturally strong affinity for collagen and stably interact with scaffolds 
made of collagen through ionic interactions[7], [15], [16]. However, these interactions mainly 
depend on the isoelectric point of the growth factor[7], [17] and the release profile is often 
characterized by an initial burst[7]. Therefore, it does not constitute the optimal manner to control 
the release of growth factors. 
A variety of techniques have been developed for the covalent chemical conjugation of growth 
factors to collagen scaffolds so as to provide a highly localized and long-lasting signaling. The 
random covalent grafting of growth factors has proved worthwhile[18], [19], in particular through 
the NHS/EDC coupling chemistry that targets free amine groups on the growth factor[20] or by 
photo-irradiation[21]. However, the bioactivity of the immobilized proteins may be negatively 
impacted, since their attachment to the substrate may mask or alter their receptor binding 
moieties[22], [23]. The covalent binding of growth factors in an oriented manner with the help of 
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a cysteine tag has also been investigated[24]. However, the addition of a cysteine can hamper 
protein folding via the formation of unwanted disulfide bridges, hence resulting in a loss of 
bioactivity. Importantly, the covalent binding of growth factors may also prevent their endocytosis, 
which can be crucial for signaling[25]. 
The tethering of growth factors in a stable but non-covalent manner through specific affinity tags 
has also been extensively studied. The major strategies that have been tested include the 
interactions between biotin and streptavidin[26], coil peptides[27]–[29], DOPA-containing 
peptides[30] as well as the use of binding domains for heparin/heparan sulfate[31], laminin[32], 
fibrin[33] or fibronectin[34]. Among them, the use of several collagen-binding domain (CBD) 
fusion proteins in association with collagen-based biomaterials has been the subject of intense 
research. Indeed,  type I collagen is the most abundant protein in the human body[35]; it is found 
in the extracellular matrix of bones, skin, tendons, cornea, artery walls as well as internal organs. 
Hence, a recombinant collagen-binding growth factor being tethered to a resorbable collagen 
biomaterial would also bear the potential to bind to the extracellular collagenous matrix after 
resorption of the implant, which would significantly improve its bioavailability over time. 
The purpose of this review is (i) to examine the various CBDs that have been characterized and 
discuss how their origin and size affect their affinity and specificity for collagen, and (ii) to assess 
to which extent collagen biomaterials functionalized with CBD fusion proteins have emerged as 
powerful tools in the fields of wound healing and bone regeneration. 
3.4 Collagen-binding domains 
The term collagen-binding domain (CBD) encompasses very distinct polypeptide domains that are 
either engineered or derived from native collagen-binding proteins such as fibronectin, the von 
Willebrand Factor and several collagenases. This diversity of origin results in a great heterogeneity 
of sizes, as they range from a seven amino-acid long peptide to a whole protein domain of 42 kDa 
(Table I). Bearing in mind that these domains will be fused to growth factors and that controlled 
release is critical in tissue engineering and regenerative medicine, it is crucial to assess how their 
sequence and their length affect their interaction with collagen, especially in terms of stability.  
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 Quantitative characterization of CBD-collagen interactions 
For most of the CBDs studied in the literature, the strength of their interaction with collagen has 
been determined, either by reporting an apparent affinity, or thermodynamic association constant 
(KA, expressed in M
-1), or its inverse, the thermodynamic dissociation constant (KD, expressed in 
M). A plethora of dissociation constant values, spanning from the low nanomolar to the 
micromolar, have been determined for the various CBD-collagen interactions (see Table I). These 
differences in apparent affinities may not be surprising given the diverse origins of the CBDs and 
types of collagen. Such a range of affinities may be exploited to target specific types of collagen 
by selecting an appropriate CBD or to modulate the release of a given protein fused to a specific 
CBD by virtue of its affinity for collagen. However, in order to avoid any misinterpretation of the 
data presented in Table I, one may analyze them with caution.  
Many techniques have indeed been employed by the research community to determine the affinities 
of the various CBDs for the different types of collagen. Those include Surface Plasmon Resonance 
(SPR)-based biosensor assays[36], Enzyme-Linked Immunosorbent Assays (ELISA)[14], 
radioactivity assays by using iodinated proteins[37] as well as fluorescence titration assays by 
measuring changes in anisotropy of fluorescein-labeled collagen chains[38]. All of these methods 
have their own merits and limitations to assess an apparent dissociation constant[39]. Interestingly, 
large differences can be pinpointed between the values derived from distinct techniques within the 
same report. For example, when characterizing the interactions between the von Willebrand A1 
domain for type III collagen, Morales et al. determined an apparent KD of 8 nM by SPR and of 400 
nM by ELISA[40]. Such a discrepancy can result from several biases inherent to the techniques at 
hand: in most SPR assays, the collagen is covalently attached to the biosensor surface, whereas, in 
ELISA, the substrate is non-specifically adsorbed at the bottom of the well. Both approaches may 
lead to distinct alterations of the three-dimensional conformation of the triple helix of collagen and, 
as a result, change the strength of its interaction with CBDs[40]. Other artefacts related to 
inappropriate assay conditions, as those documented in specialized reports[41], [42] may also be 
invoked to explain these discrepancies. 
It is also not uncommon that distinct research groups report different apparent KD for the same 
interaction, even when assessed with the same assay (see Table I). For example, Sun et al. reported 
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an apparent KD of 5.5 nM for the capture of the fusion protein TKKTLRT-PDGF (platelet-derived 
growth factor) by a type I collagen membrane, whereas Lin et al. reported an apparent KD of 97 
nM for the same protein incubated on type I collagen-coated wells[43], [44]. As much as the 
techniques, the procedure for data processing and KD determination may therefore be worth 
questioning. In most of the articles here reviewed, the apparent KD values were indeed derived by 
linearizing the experimental data, via a Scatchard plot for instance. Such an approach is prone to 
introduce errors and biases[45], especially when the plot deviates from linearity and when data are 
omitted[46], [47].  
 
To overcome these limitations, we here propose a rationalized method for data processing. By 
curve-fitting the complete data set with the GraphPad Prism 6 Software (GraphPad Prism Software 
Inc., San Diego, CA), using a Hill-type equation that assumes a 1:1 interaction, the half-maximum 
effective concentration (EC50) of a CBD binding to collagen can be calculated:  
𝑌 =
𝑌𝑚𝑎𝑥 
1 +
𝐸𝐶50
[𝐶𝐵𝐷]
 
Where [CBD] and Y correspond to the incubated CBD concentration and the corresponding 
response (signal minus blank), respectively. Ymax, the theoretical maximal response, and EC50, the 
half-maximum effective concentration, are outputs. Note that the Hill slope was fixed at 1.0 for the 
sake of comparison. 
This curve-fitting method was applied to all the CBD-collagen interaction studies, when raw results 
were available, by extracting the data from the research article figures using the WebPlotDigitizer 
3.9 software[48]. When applicable, the EC50 values derived from the fits, the coefficient of 
determination (R²) as well as the number of experimental data points extracted from the figures (n) 
are given in Table I, in addition to the apparent dissociation constant value (KD) that was reported 
by the authors. Although all R² values were close to 1, which is indicative of a good fit between 
the model and the data, some research groups have used a low number of CBD concentrations in 
their investigation. Given that the reliability of any curve-fitting is highly dependent on the number 
of experimental points, both the KD values they reported and the EC50 values we calculated need 
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to be treated with caution. Furthermore, we encountered several cases of biphasic interactions, for 
which we provided only the lowest EC50 (corresponding to the highest apparent affinity).  
With this analytical approach, we found that the interaction of TKKTLRT-PDGF for type I 
collagen, with reported KD values of 5.5 nM and 97 nM by Sun et al. and Lin et al., respectively, 
was best depicted by an EC50 of 1 100 nM in both cases[43], [44]. This calculated value is plausible, 
given that the majority of the TKKTLRT fusion proteins have a dissociation constant in the low 
micromolar range (Table I). 
 Fibronectin 
Fibronectin (FN) is a 220-kDa protein of the ECM which exists as a dimer and binds to many 
biological partners such as collagen, fibrin, heparin and integrins (Fig. 1A). FN has a very high 
apparent affinity for the type I (KD = 13 nM)[49] and type II (KD = 58 nM) collagens[50], and it 
binds even more strongly to their denatured form, gelatin[51], (KD = 2 nM)[50], which suggests 
that the binding site(s) within collagen are, at least partially, masked in the native triple helix[49], 
[52]. 
The CBD of FN is a 42-kDa domain composed of six modules ( I6-II1-II2-I7-I8-I9, see Fig. 1A) that 
are all required for full affinity[53], supporting a cooperative mode of interaction where all modules 
simultaneously participate[54], [55]. The FN type II modules are found in many other proteins, 
including the mannose receptor[56], the Factor XII[57] and the matrix metalloproteinase 2 
(MMP2)[55], providing them with collagen-binding ability. Similar to the full-length FN, its CBD 
displays a higher affinity for gelatin than for properly folded collagens. The CBD of FN is however 
monomeric and has a moderate affinity for type I collagen (KD = 420-800 nM)[49], [58], hence 
highlighting the importance of FN dimerization (and of the resulting avidity) for optimal binding 
to collagen. Numerous subdomains containing three or more modules have been studied, including 
a short peptide sequence extracted from the module I9, CQDSETRTFY, which binding to type I 
collagen proved to be very weak (EC50 = 900 000 nM, Table I)[59], [60]. 
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Figure 3.1. Structure of several proteins which contains a collagen-binding domain (in red): human 
fibronectin (A), von Willebrand Factor (B), placental growth factor (C), C. histolyticum 
collagenases ColG and ColH (D), decorin (E) and S. aureus adhesin (F). 
 
 Von Willebrand Factor 
The von Willebrand Factor (vWF) is a 275-kDa blood glycoprotein involved in hemostasis that is 
frequently encountered as a multimer (due to disulfide bonds), which improves its hemostatic 
potential[61]. The mature vWF has a very high affinity for type I (KD = 1.8 nM)[62], type III          
(KD = 3.4 nM)[63] and type VI (KD = 8 nM)[64] collagens. It poorly binds to denatured collagen, 
in stark contrast to FN[65], [66]. Several moieties of the vWF have been studied for their ability to 
bind to collagen (Fig. 1B), in particular the A1 (20.3 kDa) and A3 domains (19.3 kDa)[67]. 
Although conflicting results exist in the literature, the A1 domain of vWF does not seem to play a 
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significant role in the binding of vWF to type I/III collagens[68], [69] but is crucial for its 
interaction with the type IV/VI collagens[64], [70], [71]. On the contrary, the A3 domain is 
considered to be the main collagen-binding site of the vWF[72], [73] and have a moderate affinity 
for the type I (KD = 1 800 nM)[67] and type III collagens (KD = 1 600 nM)[40]. The A3 domain is 
thought to interact with the RGQAGVMGF/RGEOGNIGF sequences of the α1/α2 chains of type 
I collagen and with the RGQOGVMGF sequence in type II and III collagens[69]. Shorter peptide 
sequences, derived from the bovine and human vWF have also been studied: WREPSFCALS and 
WREPGRCELN, respectively (Fig. 1B)[37]. These short peptides have often been mutated, that 
is, their cysteine residue has been replaced by a methionine (WREPSF[M]ALS or 
WREPGR[M]ELN)[74], [75] in order to avoid unwanted homodimerization or misfolding[76], 
[77]. The WREPSFCALS peptide is derived from a 21-kDa sequence (F570 - K682) of the bovine 
vWF (NP_001192237.1), described by Takagi et al.: this sequence is located at the end of the vWF 
propeptide[78] which is cleaved during posttranslational modifications of vWF[79]. As opposed to 
the A3 domain, the affinity of the WREPSFCALS peptide for type I collagen is very weak (EC50 
= 29 000 nM, Table I)[37]. Nonetheless, it binds to all collagen types from I to V, in addition to 
gelatin[37]. Its 21-kDa parent fragment possesses the same characteristics but displays a higher 
affinity for type I collagen (EC50  = 780 nM, Table I)[37]. 
 Placental Growth Factor 
Another protein from which the potential of its short CBD has been recently highlighted is the 
Placental Growth Factor (PlGF, 16.7 kDa), a member of the VEGF family, that is essential for 
angiogenesis, in particular over the bone-marrow derived cells[80]. The sequence analysis of two 
splice variants of PIGF which interact differently with the ECM, PlGF-1 and PlGF-2, allowed the 
identification of a 2.8-kDa amino acid sequence that binds to collagen 
(RRRPKGRGKRRREKQRPTDCHL, Fig. 1C)[14]. Indeed, while initially considered as a heparin 
binding domain[81], this sequence binds very strongly to type I collagen (KD = 126 nM) and even 
more to Fibronectin, Vitronectin, Heparan Sulfate and other ECM proteins[14]. Although this 
sequence has a very high isoelectric point (pI = 12.0), electrostatic interactions only are not 
sufficient for collagen binding since a scrambled version of this peptide does not bind to type I 
collagen[14]. Conversely, Martino and colleagues assessed that the cysteine at the C-terminus of 
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the sequence can be mutated to a serine with little to no influence on the interaction with type I 
collagen[14]. No further experiment has been reported yet concerning the specificity of this CBD 
towards the other collagen types. 
 C. histolyticum collagenases 
ColH (116 kDa) and ColG (126 kDa) are two collagenases from the pathogenic Clostridium 
histolyticum (Fig. 1D)[82]. They feature a broad substrate specificity and target various types of 
collagens as well as gelatin[83], [84]. For instance the full-length ColH enzyme displays a strong 
affinity for type I collagen (KD = 99.5 nM)[85]. Their CBD, corresponding to the S3 domain (13 
kDa) for ColH and the S3a+S3b domains (26 kDa) for ColG, are often associated with the 
polycystic kidney disease-like domain that precedes them, that is S2a+S2b (20 kDa) for ColH and 
S2 (10 kDa) for ColG (Fig. 1D). 
The fragment corresponding to the S2b+S3 domains of ColH displays a biphasic interaction with 
collagen, presenting a strong affinity (KD = 339 nM) followed by a moderate affinity at higher 
concentrations (KD = 2110 nM)[85], whereas the S3 domain alone poorly binds to type I collagen 
(KD = 15 900 nM)[85]. 
The short fragment of ColG corresponding to the S3a+S3b domains (Fig. 1D) binds to all collagen 
types from I to IV, and even (POG)n (KD = 63 000 nM)[86], where (POG)n is a collagen-like 
peptide, provided that the number of repeats, n, is large enough to allow the peptide to have a triple-
helical conformation[87]. Likewise, it does not bind to gelatin, suggesting that this CBD recognizes 
the triple-helical structure of collagen[84], [86]. 
 Decorin 
Decorin is a small proteoglycan which interacts with collagen fibrils in all connective tissues[88, 
pp. 4–5]. Similarly to biglycan and fibromodulin, its core protein is mainly constituted of leucine-
rich repeats (LRR). Although the glycosaminoglycan chains play a role in the binding of decorin 
to collagen, the core protein alone also binds to all types of collagen (I-VI) with strong affinity (KD 
= 6 nM for type I collagen)[89]–[91]. Its CBD is located in the LRR 5-6[88], [89] of the core 
protein (NP_001911.1, Fig. 1E), it binds to type I collagen with moderate affinity (EC50 = 7 400 
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nM, Table I)[89]. This CBD contains a small sequence SYIRIADTNIT that is, when used as a 
single peptide, is able to specifically inhibit the interaction between decorin and type I collagen (Ki 
= 4 000 nM)[89]. 
 S. aureus adhesin 
Staphylococcus aureus is a very common opportunistic pathogen which persistently colonizes 
about 20% of the human population[92]. As a Gram-positive bacterium, S. aureus is covered with 
adhesive proteins, among which are adhesins[93]. CNA35 is a 35-kDa fragment of the S. aureus 
adhesin (CNA) that hooks the bacteria to collagen. This CBD is composed of two domains: N1 and 
N2, that can entwine the collagen triple helix (Fig. 1F)[94]. The interaction of CNA35 with the 
type I collagen shows a biphasic behavior characterized by a high affinity binding mode (KD = 500 
nM) and a low affinity component of binding (our analysis indicated an EC50 > 300 000 nM)[95]. 
To a lower extent, this CBD also binds to collagen II, III and IV, but neither to collagen V nor to 
collagen VI[95]. 
 V. mimicus metalloprotease 
Vibrio mimicus is a pathogenic bacterium which is responsible for certain cases of gastroenteritis. 
It expresses a metalloprotease named VMC, which CBD, LVLSRPGQFAQWAQT 
VKNLGEQYNAEFAVWLDT (3.8 kDa), contains two FAXWXXT repeats shown to be very 
important for its collagen-binding ability[96]. In particular, the second repeat is very conserved in 
several species of Vibrio[96]. This VMC metalloprotease targets type I, II and III collagens in 
addition to gelatin[97]. However, the 33 amino-acid-long CBD has a moderate affinity for type I 
collagen (KD = 4 000 nM)[96]. 
 Engineered collagen-binding peptides 
Another well-studied CBD that corresponds to the peptide sequence TKKTLRT has been 
engineered to be the antisense peptide of the collagenase-cleavage site within the α2 chain of type 
I collagen[98]. This peptide has almost the same hydrophilicity plot as SQNPVQP and SSNPIQP 
which are part of the matrix metalloproteinase 1 (MMP1) and the neutrophil collagenase, 
respectively[98]. TKKTLRT has a moderate affinity for type I collagen (our analysis indicated an 
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EC50 equal to 2300 nM, Table I)[98] and has the ability to bind to gelatin[99]. However, Fukata 
and colleagues demonstrated that its maximal binding capacity is significantly weaker than that of 
the fragment corresponding to the S2b+S3 domains derived from the C. histolyticum ColH[100]. 
Although its isoelectric point is very high (pI = 11.2), this characteristic is not sufficient for its 
optimal interaction with collagen as De Souza and colleagues demonstrated that a scrambled 
version (LTTTKKR) did not bind to collagen[98]. 
Other collagen-binding peptides were identified by phage display[101] or by ribosome display, an 
in vitro method for selection and evolution of peptides (unpublished results)[102]. 
 Collagen-mimetic peptide 
The collagen-mimetic peptide, also known as collagen hybridizing peptide, is composed of 6-10 
repeats of the sequence GPO (or GPP), where O is the hydroxyproline[103]. Since this peptide 
mimics collagen triple helix conformation, it has a high propensity to hybridize to collagen both in 
vitro and in vivo[103]. More particularly, it targets denatured collagen since it interacts with 
unfolded collagen strands to form a triple helical structure[104]. Collagen is frequently denatured 
in pathological conditions such as cancer, atherosclerosis, arthritis and fibrosis; the collagen-
mimetic peptide can thus be employed to target the denatured collagen for therapeutic application 
in this context[101]. It has demonstrated high specificity and high affinity for type I-V collagen, 
displaying a dissociation constant close to 10 nM, depending of the number of the repeats[105]. 
However, since it spontaneously self-assemble into helical homotrimers, it needs to be heated or 
deprotected from a photo-cleavable group, in order to be single stranded[101]. 
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Table 3.1. Reported KD and calculated EC50 of various collagen-binding polypeptides. 
See paragraph 3.4.1 for our methodological approach. 
*: the plateau (saturation) has not been reached during the experiment. 
CBD origin  Reported KD Calculated EC50   
Protein Subunit Substrate  
SPR 
(nM) 
ELISA 
(nM) 
EC50 
(nM) 
R² n Reference 
human 
fibronectin 
full-length FN 
Col I α1   13 70 0.975 15 Ingham, 1988[49] 
Col I α1     340 0.999 6 Ingham, 2002[38] 
Col II   58 75 0.991 6 An, 2014[50] 
Denat. Col II   2 3 0.980 6 An, 2014[50] 
type A gelatin 0.08     
Van Vlierberghe, 
2009[106] 
type B gelatin 2     
Van Vlierberghe, 
2009[106] 
Col IX 3     Parsons, 2011[107] 
     I6-II1-II2 Col I α1  31 000        Pickford, 2001[108] 
     I6-II1-II2-I7 
Col I   410 0.981 10 Steffensen, 2002[55] 
Denat. Col I   580 0.985 10 Steffensen, 2002[55] 
     I6-II1-II2-I7-HGF Col I     76* 0.983 6 Kitajima, 2007[109] 
     I6-II1-II2-I7-I8-I9 
Col I α1   420 610 0.995 13 Ingham, 1988[49] 
Col I   800 750 0.941 10 Ingham, 1989[58] 
Col I α2   1 800 1 200 0.995 28 Ingham, 2002[38] 
(POG)10   150 000 120 000 0.986 90 Ingham, 2002[38] 
gelatin   650 800 0.973 14 Katagiri, 2003[53] 
CQDSETRTFY Col I     900 000 0.997 6 Sistiabudi, 2009[60] 
human  
von Willebrand 
Factor 
full-length vWF 
Col I   1.8 2 0.962 10 Pareti, 1986[62] 
Col III 3.4   0.8 0.985 8 van der Plas, 2000[63] 
Col I     8 0.992 8 
Vanhoorelbeke, 
2000[110] 
Col VI  8 10 0.998 5 Hoylaerts, 1997[64] 
Col VI    3 0.988 8 
Vanhoorelbeke, 
2000[110] 
Col III     20 0.984 5 Lankhof, 1996[73] 
Col III 2        Li, 2002[36] 
Col I 30        Li, 2002[36] 
Col III peptide 2        Lisman, 2006[69] 
A1 domain 
Col I 6        Morales, 2006[40] 
Col III 10 400 430 0.932 6 Morales, 2006[40] 
A3 domain 
Col I   1 800 1 800 0.973 7 Cruz, 1995[67] 
Col III 8        Li, 2002[36] 
Col III peptide 1800        Lisman, 2006[69] 
Col III   1 600 2000 0.997 6 Morales, 2006[40] 
EGF-A3 Col I     580 0.998 5 Kato, 2007[111] 
21 kDa fragment Col I     780 0.971 9 Takagi, 1992[37] 
WREPSFCALS Col I     29 000* 0.999 5 Takagi, 1992[37] 
WREPSFCALS-bFGF 
Col I     1 300* 0.995 8 Andrades, 2001[112] 
Col I     670 0.992 7 Zhao, 2007[113] 
Placental 
Growth Factor 2 
PlGF2(123-144) Col I   126 110 0.996 7 Martino, 2014[14] 
BMP2-PlGF2(123-144) Col I   110 100 0.986 7 Martino, 2014[14] 
PDGF BB-PlGF2(123-144) Col I   96 100 0.991 7 Martino, 2014[14] 
VEGF A-PlGF2(123-144) Col I   124 120 0.994 7 Martino, 2014[14] 
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CBD origin  Reported KD Calculated EC50   
Protein Subunit Substrate  
SPR 
(nM) 
ELISA 
(nM) 
EC50 
(nM) 
R² n Reference 
C. histolyticum 
Collagenase G 
S3b 
(POG)8 547 000        Matsushita, 2001[86] 
Col I     12 000* 0.915 10 Fukata, 2014[100] 
S3aS3b 
(POG)8 63 000        Matsushita, 2001[86] 
Col I     5 200* 0.976 10 Fukata, 2014[100] 
C. histolyticum 
Collagenase H 
full-length ColH Col I   99.5 100 0.963 15 Matsushita, 1998[85] 
S3 
Col I   15 900 22 000* 0.990 17 Matsushita, 1998[85] 
Col I     12 000* 0.985 9 Fukata, 2014[100] 
S2bS3 
Col I   339 2 000 0.980 17 Matsushita, 1998[85] 
Col I     2 100 0.934 9 Fukata, 2014[100] 
(POG)8 3        Brewster, 2008[114] 
FGF1-S2bS3 (POG)8 8        Brewster, 2008[114] 
S. aureus 
CNA 
N1-N2-N3 
CNA55 
Col I   2 100 1 800 0.979 7 Xu, 2004[115] 
Col I 1300 210 290 0.997 27 Rich, 1999[116] 
Col I   2200      Zong, 2005[94] 
N1-N2 
CNA35 
Col I   200      Zong, 2005[94] 
DBS4 3        Zong, 2005[94] 
(GPO)11 140        Zong, 2005[94] 
(GPP)11 7.5        Zong, 2005[94] 
Col I   500 260 0.992 11 Krahn, 2006[95] 
Col I   21 26 0.991 11 Xu, 2004[115] 
Col I 91   17 0.988 6 Kang, 2013[93] 
V. mimicus 
metalloprotease 
Full-length VMC Col I   2100     5 Lee, 2005[96] 
CBD Col I  4000   4 Lee, 2005[96] 
Decorin 
full-length Decorin 
Col I  6 4 0.977 8 Kalamajski, 2007[89] 
Col I 21     Nareyeck, 2004[91] 
Col VI  39     Nareyeck, 2004[91] 
LRR 5-6 Col I    7400 0.977 8 Kalamajski, 2007[89] 
Engineered peptide 
TKKTLRT Col I     2 300 0.980 7 De Souza, 1992[98] 
TKKTLRT-EGF Col I   239 1 600 0.937 6 Yang 2009[117] 
TKKTLRT-VEGF Col I   430 2 400 0.963 7 Zhang, 2009[118] 
TKKTLRT-bFGF Col I     270 0.991 7 Zhao, 2007[113] 
TKKTLRT-BMP2 
Col I   270 140 0.999 4 Chen, 2007[119] 
Col I     6 600 0.979 4 Zhao, 2009[120] 
TKKTLRT-NGF 
Col I   510 4 500 0.992 4 Sun, 2007[47] 
Col I   510 6 500 0.951 6 Sun, 2010[121] 
TKKTLRT-NT3 Col I   350 850 0.973 7 Fan, 2010[122] 
TKKTLRT-PDGF 
Col I   5.5 1 100 0.971 7 Sun, 2007[44] 
Col I   92 1 100 0.991 7 Lin, 2006[43] 
TKKTLRT-PTH Col I   292 1 200 0.996 7 Wu, 2013[123] 
TKKTLRT-BDNF 
Col I   470 1 100 0.995 8 Liang, 2010[124] 
Col I   420 1900 0.944 4 Han Q, 2009[46] 
TKKTLRT-EphA4LBD Col I   430 1 500 0.990 7 Li, 2016[125] 
TKKTLRT-
PlexinB1LBD 
Col I   360 2 900 0.995 7 Li, 2016[125] 
TKKTLRT-EGFR Ab 
Col I   460 2 800 0.955 8 Liang, 2015[126] 
Col I   210 1 600 0.968 7 Liang, 2016[127] 
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3.5 Applications of collagen-binding fusion proteins 
Numerous recombinant collagen-binding proteins have been reported in the literature, most of 
which are growth factors or cell-binding domains. The majority of these fusion proteins have been 
produced in bacteria, as it can yield very high quantity of proteins, although these are not 
glycosylated. According to the UniProt database, all of the previously described CBDs - except 
those from fibronectin and decorin - are naturally non-glycosylated, and thus can be produced as 
recombinant protein in E. coli without any loss of collagen-binding activity[55], [67], [128]. In the 
specific case of FN, it is not clearly established if the glycosylation of the Asn511 residue (within 
the module I8) significantly impacts the affinity of this CBD for collagen[129]–[131]. 
This review will focus on the in vivo applications of these recombinant proteins, especially wound 
healing, bone regeneration and neuroregeneration. 
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Figure 3.2. Biological effect of various chimeric proteins containing a collagen-binding domain 
(CBD). Collagen can be functionalized with growth factors or cytokines to stimulate cell 
proliferation or differentiation (A), cells can be engineered to provide collagen anchorage through 
a GPI-linked protein (B) and collagen can be decorated with cell-binding domains to promote cell 
adhesion (C). 
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 Chimeric collagen-binding proteins for wound healing 
Wound healing is a complex process initiated by an inflammatory phase (which involves the 
clotting cascade and the recruitment of neutrophils and macrophages), followed by a proliferative 
phase (characterized by a strong angiogenesis, fibroplasia, formation of granulation tissue and 
collagen deposition) and that ends with a remodeling phase[132]. Throughout this process, growth 
factors play crucial roles as chemoattractants (EGF, FGF-1/2, PDGF, TGF-β, SDF-1α)[133], [134], 
mitogens (EGF, FGF-1/2, HGF, PDGF)[133], [135] and promoters of angiogenesis (FGF-1/2, 
NGF-β, PDGF, TGF-β, VEGF)[136], [137]. All of these factors are released in a highly controlled 
manner for an optimal spatio-temporal distribution leading to the appropriate modulation of cell 
response[135]. Hence, providing exogenous growth factors may accelerate or improve the quality 
of the wound healing process, although the success of the approach greatly depends on the carrier 
used for their topical delivery[138]. One of the major drawbacks that limits the efficacy of bolus 
injections of growth factors for wound healing is their very short half-life in vivo[139], a problem 
that is sometimes addressed by daily administration of growth factors[137]. As an alternative, 
chimeric proteins corresponding to growth factors fused to CBD have been developed to overcome 
this limitation (Fig. 2A), so as to prevent the diffusion of the growth factors while maintaining their 
bioactivity.  
 EGF 
It has been long known that the topical application of EGF may accelerate the rate of epidermal 
regeneration in the case of partial thickness skin wounds or chronic wounds, although repeated 
applications are required[12], [140]. In order to bolster EGF effect in vivo, several groups have 
engineered EGF fusion proteins displaying collagen-binding abilities.  
One of the first CBD-containing fusion protein assessed in vivo corresponded to EGF linked to the 
WREPSFMALS peptide thanks to a 12 amino-acid-long linker[74]. This fusion protein, in contrast 
to the native soluble EGF, was shown to accumulate at the sites of inflammation of the colon in a 
nude mouse model of experimental colitis and to promote complete regeneration of the intestinal 
crypts after 3 days, when administered by enema[74]. The results indicated that one administration 
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of the fusion protein was sufficient to significantly improve healing when compared to native EGF 
and suggested that it bound to the collagen exposed at the site of injury site. 
Ishikawa et al. developed a 46-kDa fusion protein with the CBD of Fibronectin (I6-II1-II2-I7-I8-I9) 
and EGF, namely FNCBD-EGF[141]. This protein had a very stable and lasting interaction with 
collagen coated dishes but it did not bind to a large extent when applied alone in a full thickness 
wound, most probably because too little collagen was exposed at the wound site[141]. However, 
the functionalization of collagen sponges with FNCBD-EGF showed very good retention of the 
growth factor up to 4 days after implantation in diabetic wounds[141]. Oppositely, a collagen 
sponge loaded with native EGF showed almost no retention, most probably due to EGF diffusion 
around the wound[141]. Similar results have been obtained with a collagen hydrogel applied on a 
diabetic wound[142], highlighting that the fusion protein can be carried within various devices. In 
addition, the authors demonstrated that this fusion protein could directly bind to injured vessels 
when administered intravascularly in a rabbit model of injured carotid artery[142]. 
However, other designs of chimeric proteins containing a CBD and EGF led to mitigated results. 
The EGF-CBD developed by Nishi et al., which contained the CBD of ColH (S2b+S3 
domains)[143] did not exhibit the mitogenic effect one would expect from its EGF moiety. 
Similarly, Kim et al. designed several chimeric proteins of EGF fused to the CBD of V. mimicus, 
either at the EGF N- or C- terminus[144]. They observed mitigated responses in term of EGF 
bioactivity as one of the CBD-EGF fusion protein did not exhibit any mitogenic effect[144]. The 
cause(s) of these loss of activity could be numerous: EGF misfolding due to the presence of a 
particular CBD (as already observed with other tagged EGF if not properly refolded[145] or steric 
hindrance of the CBD in absence of a long-enough linker[146].  
 
In summary, successful CBD-EGF chimeras have been developed for enabling the capture of the 
epidermal growth factor in several collagen-based biomaterials that were loaded prior to 
implantation, as well as in vivo capture following topical delivery without the need for a carrier. 
The latter approach may however be more promising for vascular injuries than for skin wounds, 
most likely due to differences in endogenous collagen exposure. 
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 FGF 
Fibroblast growth factors (FGF) are potent mitogens and promote neovascularization. In particular, 
acidic (aFGF or FGF-1) and basic (bFGF or FGF-2) FGF are the most studied members of this 
family. Their fusion to CBDs has been extensively assessed due to the potential benefits these 
chimeras might bear in the field of wound healing. 
Andrades et al. showed that the fusion protein WREPSFMALS-bFGF significantly reduced the 
healing time of wounds in both normal and diabetic rats when topically applied in a collagen 
hydrogel[112]. Zhao et al. compared the bioactivity of the same fusion protein with that of the 
chimeric protein TKKTLRT-bFGF, by implanting a functionalized collagen membrane in 
rats[113]. They observed that the collagen membrane functionalized with TKKTLRT-bFGF was 
more cellularized and vascularized after 7 days than the membrane functionalized with 
WREPSFMALS-bFGF[113]. Given that the latter protein has a lower affinity for collagen than the 
former (Table I), they suggested that the higher the affinity of the fusion protein to collagen, the 
higher the retention and the more significant the vascularization and cellularization[113]. 
A number of studies have then been conducted by this group to demonstrate that the TKKTLRT-
bFGF fusion protein combined with collagen membranes could prove useful to counteract many 
tissue damage situations, be it for bladder regeneration[147], full-thickness abdominal wall defect 
repair[148], uterine horn reconstruction (all in rat)[149] and extrahepatic bile duct regeneration in 
pig[150]. In all cases, very encouraging results were obtained; for example, 90 days after the 
implantation of a collagen membrane functionalized with TKKTLRT-bFGF in a rat uterine horn 
damage model, the pregnancy rate increased from 33%, when untreated, to 60% when treated with 
bFGF and to 87% when treated with TKKTLRT-bFGF[149]. 
Altogether, since the bFGF moiety naturally binds to collagen and gelatin[151], the studies 
highlighted that CBD-bFGF fusions further enhanced the biological effects of basic fibroblast 
growth factor when incorporated in a collagen scaffold. Importantly, the choice of the CBD must 
be appropriately made in the design of a collagen-binding fusion protein, as the affinity for collagen 
mediates the retention and release rate of the growth factor, in turn impacting its effects in vivo. 
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 The VEGF/PDGF family 
Vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) strongly 
promote angiogenic activity, in particular during the proliferative phase of wound healing[152], 
[153]. The translation of VEGF to clinical use in regenerative medicine is however compromised 
by its propensity to induce vascular permeability, which can lead to systemic hypotension, edema 
and even heart failure[154]. This limitation prevents its delivery in diffusible form in both 
peripheral and cardiovascular applications, due to its systemic biodistribution[14], [155]. A 
chimeric protein corresponding to VEGF fused to a CBD may thus eliminate this caveat by limiting 
VEGF diffusion.  
Ishikawa and colleagues developed in that endeavor the FNCBD-VEGF121 fusion protein (where 
FNCBD refers to full length CBD, i.e., I6-II1-II2-I7-I8-I9, Fig. 1A). After injecting the chimera into 
the injured tibialis anterior muscle in mice, they observed that it was retained for more than 24 h at 
the injection site and promoted the proliferation of interstitial cells, as opposed to native VEGF121 
or VEGF165[52]. Furthermore, in a mouse hindlimb ischemia model, the intramuscular injection of 
FNCBD-VEGF121 did not promote the mobilization of endothelial progenitor cells in the blood 
after 4 days, contrary to VEGF121 or VEGF165[52]. Altogether the results suggested that FNCBD-
VEGF121 was successfully retained in the muscle through its CBD without any systemic effect. 
More recently, Martino et al. developed two chimeric proteins corresponding to VEGF121 and 
PDGF BB fused to the CBD they identified in PlGF-2. The two proteins were tested in a diabetic 
mouse model of full-thickness wounds[14]. In comparison with the native growth factors, both 
fusion proteins significantly accelerated the closure of the wound, improved the granulation tissue 
formation and enhanced its neovascularization after 10-15 days[14]. Moreover, in comparison with 
native VEGF, the application of the VEGF-CBD drastically reduced the vascular permeability of 
the vessels when applied on the mouse ear skin, further suggesting that this fusion protein allowed 
for the separation of the angiogenic role of VEGF from its hyper-permeability activity[14]. 
Similarly, Zhang et al. fused the TKKTLRT peptide to the N-terminus of VEGF121 and 
demonstrated that the functionalization of a collagen membrane with this chimeric protein 
significantly enhanced the neovascularization of the membrane after two weeks, when implanted 
subcutaneously[118]. More, the injection of this fusion protein in a rat infarcted myocardium 
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significantly reduced the scar size, enhanced capillary growth and improved the cardiac functions 
4 weeks after injection, when compared to native VEGF121[118]. The fusion protein was also 
almost undetectable in the serum 3 to 6 h post injection, although it was still present in the infarcted 
zone. In stark contrast, native VEGF121 had diffused into the circulation[118]. Gao et al. obtained 
similar results with a collagen membrane functionalized with the same fusion protein in a rabbit 
infarcted myocardium model[156], providing strong evidence that myocardial infarction could be 
treated with a cardiac patch made of CBD-VEGF-functionalized collagen.  
Encouraging results were also reported for the treatment of full thickness skin wound in diabetic 
rats, be it by repeated injections of the same fusion protein at the site of injury[157] or via the 
application of a functionalized collagen membrane[158]. Further attempts were made, with very 
promising results, to treat extensive urethral defect in dogs[159] and full-thickness injury uterus in 
rats[160]. For example, 60 days after injection in a rat scarred uterus, the pregnancy rate at the scar 
site increased from 6% in the control group to 19% in the group treated with VEGF and to 50% in 
the group treated with TKKTLRT-VEGF[160]. 
Similarly, Akimoto et al. constructed a fusion protein with the murine VEGF164 and the S3 domain 
of C. histolyticum ColH, which was tested in a rat dorsal-skin flap model[161]. The fusion protein 
significantly decreased the necrosis rate and promoted neoangiogenesis after 7 days, when injected 
subcutaneously[161], suggesting that the bioavailability of the growth factor was prolonged. 
However, in this particular study, the injection of native VEGF164 did not show any effect on the 
necrosis rate, in disagreement with previous studies[162], [163]. 
Lin et al. developed the fusion protein TKKTLRT-PDGF BB to decorate a collagen membrane[43]. 
4 days after subcutaneous implantation, the biomaterial significantly promoted the cell ingrowth 
and neovascularization, when compared to the membrane loaded with pristine PDGF BB[43]. 
Moreover, when employed to treat rabbit dermal ischemic ulcer, the functionalized membrane 
significantly enhanced the re-epithelialization of the wound, the formation of granulation tissue 
and the neovascularization 14 days after implantation[44]. 
Altogether, CBD-VEGF fusions may have solved the major limitation of VEGF regarding its 
clinical translation, that is, the separation of its angiogenic properties from its negative impact on 
vascular permeability. More, the collagen-binding fusion proteins of VEGF and PDGF can be 
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administered to enhance the repair rate and extent in various types of wounds, by increasing the 
bioavailability of the growth factors, when compared to their native counterparts. 
It is here worth mentioning that the high-molecular weight isoforms of VEGF possess a heparin-
binding domain that can be used to improve their retention[164], be it via interaction with 
endogenous heparan sulfate or with a heparinized biomaterial[165]. However, the interaction of 
VEGF with endogenous heparan sulfate may be less stable than those of CBD-VEGF with 
collagen, since the administration of the native growth factor do not yield the same effects, as 
observed in most of the above-mentioned studies that used VEGF165 as control. 
 HGF 
The hepatocyte growth factor (HGF, also named scatter factor) is an important cytokine in wound 
healing, given that it induces granulation tissue formation, promotes angiogenesis and accelerates 
re-epithelialization in vivo[166]. HGF synthesis and production are however complex insofar as 
they require the cleavage and processing of a single chain precursor by an enzyme, the HGF 
activator, leading to a mature heterodimer protein composed of the ɑ and β chains[167]. 
Kitajima et al. engineered a 120-kDa chimeric protein corresponding to a shortened CBD derived 
from Fibronectin (I6-II1-II2-I7) fused to HGF and expressed it in Sf9 cells, an insect cellular 
platform that provides high levels of secreted proteins[109]. In vitro, the chimera stimulated the 
growth of human umbilical vein endothelial cells for more than 10 days, in contrast to the native 
growth factor that was rapidly internalized and degraded[109]. Seven days after the implantation 
of a collagen sponge in rats, the fusion protein significantly promoted neovascularization within 
the scaffold when compared to a sponge loaded with native HGF[109]. Moreover, the team 
reported that the density of blood vessels increased in a FNCBD-HGF dose-dependent 
manner[109], suggesting that the functionalization of the biomaterial could be fine-tuned for a 
specific application. Similarly to FNCBD-EGF, the fusion protein FNCBD-HGF did not 
accumulate in the wound to a larger extent than native HGF when applied topically in a dorsal full-
thickness wound model[168], more likely due a limited exposure of endogenous collagen. This 
corroborates once again that the effectiveness of a collagen-binding fusion protein is bolstered 
when combined with the appropriate niche or carrier, such as a collagen hydrogel or a collagen 
membrane.  
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The FNCBD-HGF fusion protein was also tested in vivo by Ota et al. to treat a myocardial defect 
in pig, using a cardiac patch based on a collagen-containing urinary bladder matrix[169]. After 60 
days, the functionalized patch significantly improved the recovery of the mechanical and 
electrophysiological functions of the myocardium when compared to a patch made of Dacron[169]. 
Of salient interest, Ohkawara et al. demonstrated that this protein accelerated the re-
endothelialization of a rat carotid artery that had been injured by a balloon procedure. More 
precisely, re-endothelialization was observed when the protein was infused directly in the artery 
for 15 min, whereas infusion with native HGF did not exert such a healing effect[170]. However, 
this treatment significantly aggravated the hyperplasia of the neointima, most probably due to a 
higher local HGF concentration or a longer HGF half-life, which aggravated the stimulation of 
smooth muscle cells proliferation[170]. 
Altogether, although the production of recombinant HGF and HGF-derived chimeras is complex, 
the propensity of CBD-HGF fusions to enhance healing in vascular wounds has been demonstrated. 
Importantly, HGF potent mitogenic activity on smooth muscle cells requires their dosage to be 
tightly regulated, so as to mitigate hyperplasia. 
 Cell therapy 
A significant improvement upon the localized administration of growth factors could be achieved 
by delivering specific cells at the site of injury and guiding them towards exposed endogenous 
collagen in vascular wounds. 
This innovative concept was elegantly introduced by Tan and colleagues who engineered a fusion 
protein composed of the A3 domain of vWF and a glycosylphosphatidylinositol (GPI) anchor, a 
glycolipid naturally displayed at the cell membrane[171] (Fig. 2B). This glycosylated chimeric 
protein was produced in Chinese ovary hamster cells and used for the surface-functionalization of 
bone-marrow-derived endothelial progenitor cells (EPC). More specifically, EPCs were incubated 
with the vWF-GPI chimera which penetrated their lipid bilayer, thus providing them with a 
collagen-binding capacity. The CBD-displaying cells were then infused in the artery of a mouse 
suffering from a carotid injury. A significantly higher number of cells were incorporated at the site 
of injury, which led to an improved re-endothelialization of the artery when compared to the control 
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animals, in which the injected cells had their extracellular A3 domain cleaved from the GPI anchor 
prior to infusion[171]. 
A similar innovative approach has been developed by Shao and colleagues, who used a polypeptide 
containing both the collagen-binding sequence TKKTLRT and the cell-binding peptide 
EPLQLKM (the latter was identified by phage display and has a high specific affinity to bone 
marrow-derived mesenchymal stem cells, MSCs)[172]. Upon implantation in pig full-thickness 
wounds, collagen membranes functionalized with this polypeptide improved the healing rate, 
displaying numerous infiltrating cells and high blood vessel density, in stark contrast with the 
collagen membrane alone[172]. Although these results suggest that the polypeptide enhanced the 
capture of autologous MSCs at the wound site, further studies would be required to confirm the 
efficiency of this capture system. 
Although cell-based therapy may still be controversial and in its early stages, CBD-cell fusions 
have proved to be effective in accelerating wound healing in animal models. 
 
 Chimeric collagen-binding proteins for bone regeneration 
Bone regeneration is an intricate process regulated by numerous cytokines and growth factors. 
Similar to wound healing, these bioactive molecules play different roles, from chemoattraction 
(BMP, FGF, PDGF, VEGF, TGF-β)[173] and cell proliferation (FGF, IGF, PDGF, TGF-β)[173] 
to osteoinduction, i.e. differentiation of MSCs into mature bone cells (BMP, IL-11, TGF-β)[173]. 
Exogenous growth factors can thus be employed to functionalize scaffolds, such as demineralized 
bone matrix (DBM, made of spongy bone treated with HCl), in order to promote osteogenesis[33]. 
Some of these growth factors are already approved by the Food and Drug Administration (FDA) 
for bone regeneration purposes: for example, BMP2 can be administered to accelerate the healing 
of open tibial fractures[174]. However, the clinical translation of the other growth factors is 
seriously limited by the lack of control of their spatiotemporal release and the high doses that are 
required, which may lead to side-effects such as heterotopic bone formation or increased risks of 
cancer[33]. In this context, collagen-binding fusion proteins were shown to be very appealing to 
better control the localization of growth factors. In addition to being the main organic content of 
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bone, type I collagen is indeed the basis of several resorbable biomaterials that have already been 
approved by the FDA for bone repair[175], [176]. 
 FGF 
Within the context of bone regeneration, bFGF represents once again a potent mitogenic growth 
factor that is secreted by many cell types, including MSCs and osteoblasts[173], [177]. In the early 
phase of fracture healing, bFGF is associated with a rapid increase in the local amount of 
MSCs[173], [178]. Accordingly, exogenous bFGF is known for promoting callus formation and 
bone healing[173], [178]. 
In order to obtain a large quantity of chondrocytes, Du et al. cultivated MSCs in a 3D scaffold 
made of chondroitin sulfate and gelatin that was loaded with either both native TGF-β and bFGF 
or TGF-β and TKKTLRT-bFGF[179]. While half of the untagged bFGF was released from the 
scaffold within 1 day, the half-time of the release of its CBD-tagged version was almost 5 days. In 
fact, two distinct interactions control the release profile of both growth factors: on the one hand, 
the CBD interacts with gelatin and, on the other hand, bFGF and TGF-β bind to chondroitin sulfate 
owing to electrostatic interactions. The resulting functionalized 3D matrix proved to be an excellent 
cell niche for promoting the in vitro differentiation of MSCs into chondrocytes[179]. In addition 
to highlighting the potential of a CBD-FGF construct for bone regeneration, this study 
demonstrated how the combination of two distinct interactions can be exploited to potentiate the 
growth factors effect when embedded in an appropriate scaffold. 
In an attempt to improve fracture healing, Saito et al. demonstrated the benefits of combining the 
administration of collagen powder with a CBD-bFGF fusion protein comprising the S2b+S3 
collagen-binding domain of the ColH collagenase[180]. Four weeks after treatment of femoral 
fractures in mice, bigger callus volume and higher bone mineral content were produced, in 
comparison with the same collagen powder loaded with native bFGF[180]. In particular, Ueno and 
colleagues demonstrated that this treatment accelerated the bone union in a mice femur graft model, 
showing that a hard callus bridge was formed at the host/graft junction[181]. 
Moreover, Uchida et al. studied the impact of varying the affinity of the fusion protein for collagen 
by designing chimeric proteins corresponding to bFGF fused to various CBD versions, i.e. the 
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S2b+S3 domains or the S3 domain alone. Once combined with a collagen sheet and applied in a 
rat femur graft model, bFGF-S2b+S3 markedly enhanced bone formation in comparison with 
bFGF-S3[182]. This experiment confirmed that the affinity of the fusion proteins for collagen is a 
key factor in their efficacy, as S2b+S3 has higher affinity for collagen (see Table I). 
In addition, this group demonstrated that the fusion protein bFGF–S2b+S3 can be combined to a 
large panel of collagen carriers, such as collagen powder derived from porcine skin[180], collagen 
sheet[183], demineralized bone matrix[183], demineralized bone powder[184], or even (POG)10, a 
polymer which mimics collagen triple helix conformation[185]. 
In short, CBD-bFGF can be administered along with a large panel of collagen biomaterials to 
improve bone regeneration. However, the efficacy of the approach is largely driven by the affinity 
for collagen of this fusion protein. 
 The TGF-β family 
TGF-β growth factors exert their role on many different cell types in the human body; in particular, 
they stimulate the migration and the proliferation of osteoprogenitor cells[173]. In addition, TGF-
β1 was reported to promote early stage of osteoblast differentiation while inhibiting osteoinduction 
and mineralization at later stages[173]. 
Andrades et al. thus developed the fusion protein WREPSFMALS-TGF-β1 and demonstrated that 
its chemotactic activity was much higher than that of native TGF-β1, BMP2, BMP7 or even bFGF, 
by observing the migration of rat primary bone marrow cells cultivated in a collagen hydrogel[186]. 
More, the mitogenic activity of this fusion protein over rat MSCs was significantly higher than 
pristine TGF-β1, leading cells to form numerous colonies, similarly to BMP2 and BMP7 but much 
earlier in the differentiation process[186]. Conversely, calcium deposition, osteocalcin synthesis 
and ALP activity – all markers of osteogenic lineage – were also promoted in comparison with 
TGF-β1, although they did not reached the values induced by BMP2 or BMP7[186]. Overall, the 
chimeric collagen-binding TGF-β1 displayed a higher mitogenic activity than its native form, along 
with osteoinductive effects in the early phase of differentiation, whereas TGF-β1 had little to no 
effect. Similar results were obtained with human bone-marrow derived MSCs[187]. When the 
MSCs were implanted subcutaneously into diffusion chambers, the cells that had been pretreated 
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WREPSFMALS-TGF-β1 strongly promoted chondrogenesis, as cartilage accounted for 45% of the 
neoformed tissue, in comparison with the cells treated with native TGF-β1 (25%)[186], though 
none promoted bone formation. Claros et al. demonstrated that the complete osteoinduction of 
bone-marrow derived MSCs could be easily reached by switching WREPSFMALS-TGF-β1 to 
BMP2 on the later stages of differentiation, before implanting them subcutaneously into a diffusion 
chamber[188]. 
Attempts were also made to engineer a collagen-binding fusion with the TGF-β2 isoform, but no 
further in vivo characterization were made[189]. 
In summary, the CBD-TGF-β1 fusion proteins display significantly more potent chemotactic, 
mitogenic and osteoinductive activities than the pristine TGF-β1. The collagen-binding ability of 
the fusion proteins is more likely accountable for these effects, as it enhances the half-life of the 
chimeric proteins. 
 The BMP subfamily 
The bone morphogenetic proteins (BMPs) belong to the large TGF-β family, they constitute a 
subfamily of key players in the regulation of osteoinduction. In bones, they are mainly synthesized 
by skeletal cells, such as osteoblasts[173]. BMP2 and BMP4 are striking examples of BMPs 
harboring osteoinductive properties: in vivo, they are known to promote the recruitment of MSCs 
and their differentiation into osteoblasts, resulting in ectopic bone formation[173]. In contrast, 
BMP3 is known for inhibiting osteoblast differentiation by interfering with osteogenic BMP 
signaling and is thus a negative regulator of bone density[190], [191]. It however promotes the 
proliferation of MSCs[192]. 
In an effort to promote bone regeneration, Chen et al. designed two BMP2 chimeric proteins C-
terminally fused to a collagen-binding peptide, either WREPSFCALS or TKKTLRT. After 4 
weeks, the subcutaneous implantation of DBM functionalized with WREPSFCALS-BMP2 in rats 
resulted in more ectopic bone formation in comparison with DBM loaded with native BMP2[193]. 
Similar results were observed with DBM functionalized with TKKTLRT-BMP2, leading to ectopic 
bone formation both in the center and on the outskirts of the implant. The research team reported 
that the regeneration was more homogeneous, with a higher bone density, when compared to the 
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DBM with pristine BMP2[119]. Unfortunately, a direct comparison of both fusion proteins was 
not performed by Chen and colleagues. On the same note, Visser et al. reported analogous results 
when implanting a collagen sponge that had been functionalized with the WREPSFMALS-BMP2 
chimeric protein (400 – 10 000 ng) in the dorsal muscle of rats[77]. After 4 weeks, the 
WREPSFMALS-BMP2 loaded sponge not only induced the production of a higher quantity of 
bone, but also of a more mature bone than its native BMP2 counterpart, exhibiting numerous 
trabeculae, medullar cavities and blood vessels[77]. These two independent studies thus 
complement each other. They indeed demonstrate that the osteoinductive property observed by 
Chen et al. is mainly due to the BMP2 fusion proteins, rather than the DBM, a carrier known to 
have osteoinductive properties by itself[77]. Moreover, although it is generally admitted that BMP2 
cannot induce osteogenesis under 460 ng in a rat model[194], Visser et al. showed that a quantity 
of collagen-binding BMP2 fusion protein below this threshold, i.e. 400 ng, was sufficient to induce 
bone formation, as opposed to the same quantity of native BMP2[77]. 
Chen et al. treated a critical-size rabbit mandible defect with a combination of DBM and 
TKKTLRT-BMP2 and showed that this treatment strongly promoted the healing of the mandible 
after 4 weeks. More precisely, neoformed bone occupied the main part of the defect site (80%), as 
opposed to the DBM with pristine BMP2 group (60%) and the negative control (<30%)[119], 
which suggests that this approach is promising in bone reconstruction. However, as DBM does not 
have sufficient mechanical compression strength, its application is limited to non-weight bearing 
bones. To overcome this problem, Zhao et al. studied a mineralized bone matrix (MBM) based on 
bovine spongy bone treated with H2O2, which has similar mechanical properties as untreated 
cancellous bone[120]. The team subcutaneously implanted MBM loaded with TKKTLRT-BMP2 
in rats. After 7 days of implantation, a significantly higher ALP activity was noted, demonstrating 
that the cell ingrowth was enhanced, in comparison with MBM loaded with BMP2[120]. Similarly, 
after 60 days, more bone-like tissue was formed at the site of the MBM decorated with TKKTLRT-
BMP2 implant[120]. Besides, Lai and colleagues studied the vertical bone regeneration by fixing 
titanium cylinders at the top of rabbit skulls, filling them with MBM and covering them with a 
collagen membrane being, functionalized with the TKKTLRT-BMP2 construct[195]. After 6 
weeks, they observed that new bone formation was promoted not only from the surface of the 
native bone, but also from the superficial structures in contact with the collagen membrane[195], 
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suggesting that the functionalized membrane induced bone formation within the cylinder (such was 
not the case for the membrane loaded with pristine BMP2). 
As an alternative to the collagenase-derived CBD, Martino et al. engineered two chimeric proteins 
corresponding to BMP2 and PDGF BB fused with the CBD of PlGF2[14]. Their topical delivery 
in a rat critical-size calvarial defect significantly increased bone tissue deposition (75% coverage 
of the defect) and the number of mesenchymal stem cells/pericytes, in comparison with wild type 
growth factors (<50% coverage of the defect)[14]. This experiment demonstrated that, even in the 
absence of carrier, the collagen-binding domain from PIGF2 may favor the recruitment of the 
fusion proteins by the animal extracellular collagenous matrix and promote bone regeneration. 
The tethering of other members of the BMP family was also investigated. For example, Han et al. 
functionalized collagen sponges with WREPSMALS-BMP3 fusion protein and implanted them 
subcutaneously in rats [196]. After 4 weeks, in comparison with the controls (collagen sponges 
loaded with native BMP3), the retrieved implants exhibited significantly more calcium deposition, 
which increased in a BMP dose dependent manner[196]. However, the retrieved implants did not 
present any sign of bone formation or any increase in the ALP activity[196], a marker of the 
osteoblastic differentiation[191]. A comparison of these results with those of Visser et al. 
consistently corroborated the fact that BMP3 alone does not have the ability to promote 
osteogenesis, as opposed to BMP2. However, Han et al. reported that, when collagen sponges (or 
collagen-coated ceramic blocks) were functionalized with WREPSMALS-BMP3, their 
introduction in a rat calvarial defect did promote bone repair after 4 weeks (as did native BMP3 to 
a lesser extent)[196]. 
Another BMP member, BMP4, was also studied by Lu et al., who engineered a BMP4 chimeric 
protein containing the full-length CBD of Fibronectin (I6-II1-II2-I7-I8-I9). The chimera production 
was achieved in transgenic silkworm[197], a system that provides high level of protein expression, 
along with post-translational glycosylation[198]. A collagen-PLGA hybrid scaffold was 
functionalized with CBD-BMP4, seeded with MSCs to induce in vitro osteogenic differentiation 
for 24h. The scaffold was then implanted subcutaneously in rats[197]. After 4 weeks, calcium 
deposition was observed in the CBD-BMP4 group, in stark contrast with all controls (native BMP4, 
CBD alone or PBS)[197]. Similarly, osteogenic markers were strongly expressed in the CBD-
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BMP4 group, but not in the others[197], suggesting that the differentiation of the cells was due to 
the long lasting action of CBD-BMP4 that had been retained within the scaffold due to its CBD 
moiety. These results were supported by Shiozaki et al., who injected as little as 100 ng of CBD-
BMP4 in a mouse cranial bone defect: after 2 weeks, substantial ingrowth of new bone formation 
was observed. In particular, the ossification area of the defect was significantly improved (~58%), 
in comparison with the BMP4 group (~37%), the CBD group (~23%) and the control group 
(~19%). Interestingly, the authors showed that the CBD of fibronectin itself had a small positive 
effect upon induction of bone formation, leading to potential synergistic osteogenic effects with 
the BMP moiety[197]. In an effort to treat osteochondral defects, Mazaki et al. also proposed to 
combine chimeric BMP4 with a photo-cross-linkable gelatin scaffold to be loaded with bone 
marrow-derived stromal cells[199]. In a rabbit model, this implant led to the repair of subchondral 
bone via the generation of de novo articular cartilage-like tissue[199]. 
In brief, the chimeric CBD-BMP family can strongly promote bone formation or bone 
reconstruction in vivo, although each BMP family member has its own specificities. They have 
shown to be a promising treatment in several bone defects, when administered in a proper collagen 
carrier, which can be adapted to meet the mechanical properties required for each application. 
 Parathyroid hormone 
As opposed to growth factors that have a localized mode of action, the parathyroid hormone (PTH) 
is a major systemic regulator of bone metabolism[173]. It is well established that repeated 
subcutaneous injections of PTH increases bone formation, which is why PTH is an effective 
treatment for osteoporosis[173]. However, its clinical application is limited, on the one hand due 
to its side effects (hypercalcemia and tumor risk) and on the other hand due to the necessity to 
perform repeated injections for optimal positive effects[200]. In an effort to limit PTH injections, 
Ponnapakkam et al. designed a fusion protein, PTH1-33–CBD, that contained the CBD of ColH (S3 
or S2b+S3), to be either injected intraperitoneally or delivered intravascularly. The rationale was 
to promote bone regeneration on the long term by increasing PTH half-life[201]. In a mouse model 
of chemotherapy-induced osteoporosis, a single dose of PTH–CBD administered before the 
chemotherapy treatment was sufficient to improve bone mineral density and blood ALP activity of 
the mice, bringing them closer to their normal threshold after 8 weeks[201]. Of salient interest, the 
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fusion protein that contained the fragment corresponding to the S2b+S3 domains did not exhibit 
the same bioactivity in vivo as that with the S3 domain only. More specifically, the chimera that 
contained the longest CBD had no positive effect on bone mineral density, although it improved 
blood ALP activity[202], most likely due to the higher affinity of the chimera for collagen (Table 
I). In ovariectomized rats, a well-described animal model for postmenopausal osteoporosis, the 
monthly subcutaneous injection of PTH-S3 promoted a significant increase (+14%) in the bone 
mineral density of the rats, as opposed to native PTH (temporary increase +5% after 14 daily 
injections), despite its clearance from serum after 12h[200]. In addition, there was no observed 
hypercalcemia in the PTH-CBD treated animals, suggesting that this side effect was reduced thanks 
to the collagen-binding ability of the fusion protein[200]. 
In summary the administration of CBD-PTH chimeric protein can extend the systemic effect of 
native PTH, hence reducing the need for repeated injections and associated risks. Interestingly 
enough, the fusion protein harboring the highest affinity for collagen was not the more efficient for 
this specific application. 
 Cell binding domain 
The RGD sequence, originally identified in FN, has been long known to be recognized by 
integrins[203], [204]. By providing cell with anchorage, this interaction can promote their 
migration, differentiation and even their proliferation[204]. 
Visser et al. produced the peptide WREPSFMALSGRGDS containing the CBD derived from vWF 
and the RGD tripeptide[205] (Fig. 2C). They loaded collagen sponges with the native growth factor 
BMP2 along with this peptide, before implanting them intramuscularly in rats[205]. The BMP2-
RGD combination significantly promoted the osteogenesis in the implant, which included bone 
trabeculae and mineralized matrix after only 14 days of implantation[205]. In comparison, the 
implant functionalized only with BMP2 did not promote trabeculae organization and presented 
almost no calcium deposition, due to the subfunctional quantity of BMP2 employed (300 ng)[205]. 
Similarly, the RGD peptide alone did not promote any osteogenesis, indicating that the BMP2-
RGD fusion enhanced the recruitment of cells into the implant and promoted osteogenesis. 
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Similarly, Won et al. engineered a 47-kDa fusion protein containing the sequence TKKTLRT fused 
to the osteocalcin (OC) protein (a marker of the late stage of the osteogenic lineage) and to the FN 
fragment FN9-10, known for its cell-binding ability, resulting in the fusion protein TKKTLRT-OC-
FN9-10[206]. They treated critically-sized rat calvarial bone defects with collagen-coated 
polycaprolactone (PCL) scaffolds functionalized with the fusion protein. After six weeks, these 
implants significantly improved osteogenesis, with bone covering more than 50% of the defect, in 
comparison with the collagen-coated PCL scaffold (~30%) or the negative control (<15%)[206]. 
Unsurprisingly, the effects were dose-dependent, as the best results were obtained with the greatest 
amount of engineered protein. These results, along with an in vitro study[207], suggested that the 
two fragments of the fusion protein, OC and FN9-10, play a synergic role in the colonization of the 
biomaterial by MSCs and their osteoinduction[208]. 
In summary, collagen-binding fusion proteins displaying a cell-binding ability can significantly 
improve cellular ingression towards collagen biomaterials, hence resulting in better osteogenesis. 
3.6 Conclusion 
In this review, we have highlighted the therapeutic potential of chimeric proteins corresponding to 
growth factors fused to collagen-binding domains for wound healing and bone regeneration, when 
these chimeric proteins are combined to collagen-containing scaffolds or coatings. Indeed, in many 
in vivo studies, the fusion of a given growth factor to a CBD has led to a drastic improvement of 
its therapeutic effect when compared to that of the growth factor administered in its soluble form. 
This enhancement is more likely attributable to a prolonged bioavailability of the growth factor; 
may it be due to the fact that the growth factor is preserved from degradation or that it is present 
for a longer period of time and at a higher local concentration in the vicinity of its cell surface 
receptors.  Of interest, the use of a chimeric CBD-GF may also limit its side-effects, as observed 
for several soluble growth factors, since it allows for their efficient sequestration at the site of 
injury. The best example of this beneficial effect is arguably that of VEGF for which its fusion to 
a CBD permitted to uncouple its angiogenic role from its hyper-permeability activity.  
In most scientific articles collated in this review, researchers report the benefits of a given CBD-
GF fusion protein when added to a single collagen-based scaffold. Despite all the promising results 
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presented therein, these data remain hard to interpret as a whole in order to establish the importance 
of the biophysical traits of the interaction between the CBD and the collagen-based scaffold (e.g. 
GF loading capacity, binding affinity and stability) upon therapeutic outcomes. 
Indeed, very few are the studies reporting the amount of the chimeric protein bound to the scaffold 
or the impact of varying this quantity. On the same note, the effect of replacing a CBD by another 
is merely addressed. A significant amount of work thus remains to be done in order to better 
characterize the interactions occurring between the various types of collagen and the different 
collagen-binding domains identified so far. These experiments are of prime importance, not only 
to resolve the discrepancies between several values listed in Table I, but also as to provide the 
research community with a broader knowledge of these interactions. We believe this 
characterization, if exhaustive, would guide the design of novel tailored CBD-GF chimeras for 
optimal therapeutic effects.  
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CHAPITRE 4 PRODUCTION ET PURIFICATION DE PROTÉINES 
CHIMÈRES – FONCTIONALISATION D’UN SUBSTRAT DE 
COLLAGÈNE 
 
Le CBD de la fibronectine a été choisi pour concevoir un adaptateur moléculaire (CBD-Kcoil), 
notamment en raison sa très forte affinité pour le collagène, dans le but d’immobiliser des facteurs 
de croissance sur un substrat de gélatine. Le substrat étudié est une surface de polystyrène 
recouverte de gélatine, qui constitue un modèle simple pour simuler la fonctionnalisation de 
biomatériaux. Plusieurs facteurs de croissance étiquetés avec une hélice alpha Ecoil ont déjà été 
développés dans notre laboratoire et j’ai eu l’occasion de développer un autre facteur de croissance 
(Ecoil-bFGF) pour compléter cette panoplie. Le substrat de gélatine a été fonctionnalisé 
successivement par CBD-Kcoil puis par un facteur de croissance Ecoil-GF, afin de former un 
complexe stable. Les propriétés de la fonctionnalisation de surface ont ensuite été analysés d’un 
point de vue cellulaire, en particulier concernant leurs effets mitogéniques et anti-apoptotiques. 
Ces résultats ont été soumis à Acta Biomaterialia sous le n°AB-16-1351. 
 
 
4.1 Article 2 - The use of a chimeric collagen binding domain of 
fibronectin to recruit coil-tagged growth factors on gelatin-based 
biomaterials 
 
Cyril Addi1, Frédéric Murschel1, Benoît Liberelle1, Nesrine Riahi1, Gregory De Crescenzo1,* 
 
1 Department of Chemical Engineering, Biomedical Science and Technology Research Group, Bio-
P2 Research Unit, École Polytechnique de Montréal, P.O. Box 6079, succ. Centre-Ville, Montréal 
(QC), Canada H3C 3A7. 
* To whom correspondence should be addressed. E-mail address: gregory.decrescenzo@polymtl.ca 
56 
 
4.2 Abstract 
In the field of tissue engineering, the tethering of growth factors in an oriented manner can enhance 
their activity and increase their half-life. We chose to investigate the capture of the basic Fibroblast 
Growth Factor (bFGF) and the Epidermal Growth Factor (EGF) on a gelatin layer, as a model for 
the functionalization of any collagen-based biomaterials. 
Our strategy relies on the expression of a chimeric protein, that is, a Kcoil-tagged collagen-binding 
domain (CBD) of the human fibronectin, to be used as an adaptor. We proved that it has the ability 
to bind simultaneously to a gelatin substrate and any Ecoil-tagged recombinant growth factors via 
E/K coiled-coil complex formation. The tethering of the growth factors was characterized by 
ELISA and surface plasmon resonance-based biosensing. The bioactivity of the immobilized bFGF 
and EGF was evaluated by a human umbilical vein endothelial cells proliferation assay and a 
vascular smooth muscle cells survival assay. We found that the tethering of EGF preserved its 
mitogenic and anti-apoptotic activity. In the case of bFGF, its capture thanks to the Kcoil-CBD 
adaptor protein, modified its natural mode of interaction with gelatin.  
Keywords— Collagen-binding domain; coiled-coil; growth factor; tethering; biofunctionalization 
 
4.3 Introduction 
Collagen is one of the most promising materials in the field of tissue engineering, given its 
outstanding biocompatibility, biodegradability, and safety[1]. Various formulations of biomaterials 
made of collagen have been developed, such as hydrogels, sponges and microparticles. Denatured 
collagen (i.e. gelatin) is often preferred to collagen, as it can be easily cross-linked to improve its 
mechanical properties and its resistance to proteolysis[4]. Many collagen-based biomaterials have 
already passed the regulatory approval, such as Orthoss®[176] and Neuragen®[209]. 
These collagen-based biomaterials can be loaded with growth factors (GF) to improve their healing 
potential, by enhancing cell adhesion and stimulating proliferation and differentiation. However, 
the lack of control over the release of the GFs represents a major drawback since the orchestration 
of their spatiotemporal delivery is very important for their optimal bioactivity[7], [8]. Recombinant 
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GFs fused to collagen-binding proteins or peptides have been engineered to decorate collagen 
biomaterials, by providing a stable but non-covalent bond with collagen. Several recombinant 
collagen binding domains (CBD) have been studied to tether growth factors, such as the short 
TKKTLRT[98] and WREPSFCALS[37] peptides, but most of them display low affinity towards 
collagen when compared to the CBD of the fibronectin, for instance[85], [106], [131]. The latter 
has already been employed for engineering fusion proteins of various growth factors such as 
EGF[141], VEGF[52], HGF[109] and BMP4[197] – but not bFGF – with very promising results 
both in vitro and in vivo. 
Basic Fibroblast Growth Factor (bFGF) is a strong promoter of angiogenesis: it acts as a 
chemoattractant and mitogen for fibroblast and endothelial cells[210]–[212]. bFGF also supports 
the self-renewal of embryonic and induced pluripotent stem cells (iPSC)[213] and it is implicated 
in several differentiation pathways[214]. Similarly, Epidermal Growth Factor (EGF) stimulates 
cell proliferation, differentiation, and survival[215]. Native bFGF is known to bind to collagen (and 
gelatin) through ionic interactions[151], whereas EGF does not. 
We here explore the potential of a chimeric protein, corresponding to the CBD of the fibronectin 
fused to a coil peptide (the Kcoil), as a versatile adaptor capable of capturing soluble GFs tagged 
with the complementary coil peptide (the Ecoil), on gelatin substrates (Figure 4.1). As a case study, 
bFGF and EGF were selected since their immobilization on cell culture substrates has been shown 
to potentiate their activity[216]. 
We employed the fusion protein Ecoil-EGF which was previously developed and characterized in 
our laboratory[22], and designed two other fusion proteins labelled with distinct coil peptides that 
bind to each other with great affinity and specificity[28]: the Ecoil peptide was fused to bFGF, 
while the CBD of fibronectin was fused to the Kcoil peptide (Figure 4.2A). After expressing and 
purifying the proteins, we evaluated their ability to bind to their partners, that is, gelatin and Ecoil-
tagged proteins for CBD-Kcoil, and the Kcoil peptide and the bFGF receptor ectodomain (FGFR1) 
for the Ecoil-bFGF fusion protein. We also confirmed the bioactivity of the Ecoil-bFGF construct 
over human umbilical vein endothelial cells. At last, we evaluated the bioactivity of Ecoil-bFGF 
and Ecoil-EGF tethered to the gelatin substrate through CBD-Kcoil. 
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Figure 4.1. Schematic illustration of an Ecoil-tagged GF tethered in an oriented manner on a 
gelatin-coated surface that had been functionalized with CBD-Kcoil. 
 (This figure was prepared using tools from Servier Medical Art: http://www.servier.fr/) 
 
4.4 Materials & Methods 
 Chemicals and reagents 
Plasmids were purchased from GeneArt, Life Technologies (Burlington, ON). IPTG was from 
Inalco Pharmaceuticals (San Luis Obispo, CA). The TEV protease was a kind gift from Prof. J. 
Omichinski (Université de Montréal, QC). His-trap HP column, Mono STM 10/100 GL column, 
ÄKTA-purifier UPC 10 system, CM5 sensor chips, HEPES buffered saline (HBS-EP) and amine 
coupling kit were purchased from GE Healthcare (Mississauga, ON). Spectra/Por® 6 dialysis 
membranes were purchased from Spectrum Laboratories Inc. (Rancho Dominguez, CA). Cysteine-
tagged Kcoil peptides were synthesized by the peptide facility at University of Colorado (Denver, 
CO) as previously reported[217]. Gelatin from porcine skin (type A) was from Sigma Aldrich (St. 
Louis, MO). FGFR1-Fc and ELISA kits were purchased from R&D systems (Minneapolis, MN). 
Human umbilical vein endothelial cells (HUVEC), EBM-2 medium and supplements (EGM-2 
single quote kit containing growth factors, fetal bovine serum (FBS), ascorbic acid, heparin and 
hydrocortisone) were purchased from Lonza (Walkersville, MD). A7r5 vascular smooth muscle 
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cells (VSMC) were from the American Type Culture Collection (Manassas, VA). DMEM/F12 and 
Pierce BCA Protein Assay Kit were obtained from ThermoFisher Scientific (Nepean, ON). Cells 
were cultured on 25 cm2 CellBIND® flasks and 96-well CellBIND® plates from Corning 
(Corning, NY). Cell proliferation reagent (WST-1 tetrazolium salt) was purchased from Roche 
Diagnostics (Laval, QC). 
 Generation of the expression vectors 
A first plasmid, pET-TRX-TEV-Ecoil-bFGF, was purchased from GeneArt. It contained the 
sequence coding for a NH2-(His)6-tagged fusion protein composed of the thioredoxin (TRX), 
followed by a tobacco etch virus cleavage site (TEV), the Ecoil peptide (i.e, (EVSALEK)5), a 
spacer (GGGS)6 and the bFGF sequence (Figure 4.2A). 
Another plasmid, pET-CBD-Kcoil encoded for a NH2-(His)6-tagged fusion protein composed of 
the collagen-binding domain of the human fibronectin[109], [141], [218] from A260 to W599, 
followed by a spacer (GGGS)6 and the Kcoil peptide, that is (KVSALKE)5 (Figure 4.2A). 
 Expression of fusion proteins 
Competent BL21(DE3) E. coli bacteria were transformed with the two plasmids and cultured at  
37 °C in LB medium (in 4 L baffled flasks, 210 rpm) supplemented with ampicillin (100 µg/mL). 
Expression was induced by adding 0.7 mM of isopropyl β-D-1-thiogalactopyranoside (IPTG) when 
the optical density (OD) at 600 nm was c.a. 0.6. Cells were harvested 5 h later by centrifugation 
(15 min at 10,000 rpm). Cellular pellets were frozen at -20 °C and then re-suspended in 50 mL of 
lysis buffer (25 mM NaPO4, pH 7.4, 500 mM NaCl, 25 mM imidazole) and passed three times 
through a French press (1000 psi, SLM-Aminco® French Press) followed by sonication, for 
complete lysis. Ecoil-EGF was expressed and purified as previously reported[22]. 
 Purification of Ecoil-bFGF protein 
The cell lysate was clarified by centrifugation (60 min at 14,000 rpm, 4 °C) and the supernatant 
was loaded onto a 5-mL His-trap HP column charged with Ni2+. The His-tagged fusion protein was 
eluted by applying a gradient from 25 mM to 500 mM imidazole (20 min at 5 mL/min). The elution 
fraction was then dialyzed against the TEV cleavage buffer (25 mM NaPO4, pH 7.4, 125 mM NaCl, 
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1 mM EDTA, 10 mM β-mercaptoethanol) using a dialysis membrane (cut-off 8 kDa) overnight at 
4 °C. The recombinant protein was subsequently treated with the TEV protease at an 
enzyme:substrate ratio of 1:80 for 2 h at room temperature and the cleavage mixture was directly 
injected onto a Mono STM 10/100 GL column that had been pre-equilibrated with 10 column 
volumes of equilibration buffer (20 mM NaPO4, pH 7.4, 125 mM NaCl). Elution was then 
performed with a NaCl gradient (from 125 mM to 1 M, 20 min at 5 mL/min). The elution fraction 
was then passed through a 0.22 µm sterile filter and kept at -80 °C. 
 Purification of the CBD-Kcoil protein 
The bacterial lysate was centrifuged (60 min at 14,000 rpm, 4 °C) and the pellet was re-suspended 
into denaturing buffer (25 mM NaPO4, pH 7.4, 300 mM NaCl, 8 M urea, 1 mM β-mercaptoethanol) 
overnight. The supernatant harvested after centrifugation (14 000 rpm, 60 min, 4 °C) was diluted 
1:1 in the lysis buffer (25 mM NaPO4, pH 7.4, 500 mM NaCl, 25 mM imidazole). It was then 
loaded onto a 5-mL His-trap HP column charged with Ni2+, previously equilibrated with a 
denaturing buffer: lysis buffer mix (1:1). The protein refolding was performed on the column (4 M 
to 0 M urea gradient for 120 min at 5 mL/min) and the protein was then eluted with 300 mM 
imidazole. The elution fraction was clarified through a 0.22 µm sterile filter and kept at -80 °C. 
 Surface plasmon resonance (SPR) assays  
All kinetic experiments were performed at 25 °C using HBS-EP as running buffer at 100 µL/min 
on a Biacore T100 biosensor, with CM5 sensor chips. Sensorgrams were double-referenced prior 
analysis[219]. 
Gelatin was covalently immobilized using the standard ligand amine coupling procedure. 
Specifically, surface carboxylic acid groups were activated by the injection of a mixture containing 
0.05 M NHS and 0.2 M EDC for 7 min, followed by the injection of gelatin at 0.1 g/L in HBS-EP 
for 7 min (at 10 L/min). Blocking was performed using 1 M ethanolamine, pH 8.5 (7 min). CBD-
Kcoil diluted in HBS-EP was injected at various concentrations for 60 s, followed by a 540 s 
dissociation period. Regeneration was performed between each cycle with 6 M guanidine 
hydrochloride. 
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Cysteine-tagged Kcoil covalent immobilization was performed as previously described[220]. 
Ecoil-bFGF was injected at 10 nM for 180 s, followed by a 180 s buffer injection. FGFR1-Fc 
(Recombinant Human FGF R1 beta Fc chimeric protein) was then injected for 180 s, followed by 
a 360 s buffer injection. Between each cycle, regeneration was performed by injecting 30 µL of 
regeneration buffer (100 mM acetate, pH 4, 2 M NaCl).  
 ELISA 
Wells of a 96-well CellBIND® plate were pre-coated for 2 h with 100 µL of PBS with 0.1% gelatin. 
100 µL of CBD-Kcoil diluted in PBS at various concentrations was then added for 1 h. 100 µL of 
Ecoil-bFGF or Ecoil-EGF diluted in PBS with 0.5% BSA were then added at various 
concentrations for 1 h. Between each step, three extensive washes were carried out with 200 µL of 
PBS-T (PBS with 0.05% v/v Tween® 20). 
Tethered growth factor quantitation was performed using a direct ELISA by addition of 100 µL of 
biotinylated anti-bFGF or anti-EGF antibody (250 ng/mL, 1 h) followed by horseradish peroxidase 
(HRP)-streptavidin conjugate (1:40, 20 min) then 100 µl of substrate solution. Between each step, 
three extensive washes were carried out with 200 µL of PBS-T. The absorbance was read at 450 
nm. Curve-fitting was performed with the GraphPad Prism 6 Software (GraphPad Prism Software 
Inc., San Diego, CA), using a Hill-type equation assuming a 1:1 stoichiometry of binding (the Hill 
coefficient was fixed at 1.0 for the sake of result interpretation). 
For the stability assay, on the first day, a 96-well CellBIND® plate was pre-coated with gelatin, 
then every day, 4 wells were functionalized with CBD-Kcoil and Ecoil-EGF as described before. 
These wells always remained filled with 100 µL of either PBS or PBS + 10% v/v FBS and the 
medium was changed every day. 
 Proliferation assay 
HUVECs were seeded at a density of 1000 cells/well in a 96-well CellBIND® plate. The cells were 
maintained in a humidified, 5%-enriched CO2 incubator at 37 °C, using a minimal medium (EGM-
2 complemented with 2% v:v FBS, 30 μg/mL gentamicin and 25 µg/mL ascorbic acid) and soluble 
Ecoil-bFGF at various concentration. 
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Cells were also seeded onto functionalized gelatin substrate wells, prepared as described in the 
preceding paragraph, and that have been extensively washed three times with 200 µL of PBS. 
The medium was changed every other day. Cell metabolic activity was probed using a resazurin 
assay. Once rinsed with PBS, the wells were exposed to a mix of resazurin (100 µg/mL in MilliQ 
water) and culture medium (10:90 v:v) for 2 h. Fluorescence was read using a spectrophotometer 
(560 and 590 nm, for excitation and emission wavelengths, respectively). The experiments were 
repeated three times. 
 Survival assay 
Rat vascular smooth muscle cells (VSMC) were seeded at a density of 2000 cells/well in a 96-well 
CellBIND® plate prepared as previously described and washed three times with PBS. The cells 
were plated in a humidified, 5%-enriched CO2 incubator at 37 °C, using complete medium 
(DMEM/F12 complemented with 10% fetal bovine serum (FBS) and 30 μg/mL gentamicin). After 
a period of adhesion (24h), the cells were washed with PBS and the medium was switched to serum-
free DMEM/F12 with 30 μg/mL gentamicin to induce the starvation. 
The medium was changed every other day. Cell metabolic activity was probed as previously 
described. The experiment was repeated three times. 
4.5 Results 
 Expression and purification of fusion proteins 
The bacterial production and the subsequent purification of the chimeric proteins corresponding to 
bFGF and CBD, being N-terminally or C-terminally tagged with the Ecoil or Kcoil peptide, 
respectively (Ecoil-bFGF and CBD-Kcoil, Figure 4.2A) were assessed by SDS-PAGE. Under 
reducing conditions, the migration patterns of the affinity-purified chimeric proteins confirmed the 
high purity of the products and were consistent with their theoretical molecular weights, that is, 
49.0 kDa for CBD-Kcoil and 39.8 kDa for TRX-TEV-Ecoil-bFGF, respectively (Figure 4.2B). 
However, the Ecoil-bFGF chimera (22.9 kDa) did not migrate to where expected since it was 
located above the 25 kDa marker. This behavior could be attributed to the Ecoil moiety, which 
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most likely affected the migration of the chimera, similarly to what had been already observed in 
the case of Ecoil-EGF[22]. 
The yields of these protein productions were of 1.1 mg and 1.9 mg of pure protein per liter of 
bacteria for Ecoil-bFGF and CBD-Kcoil, as determined by ELISA against bFGF and in a BCA 
assay, respectively. 
 
Figure 4.2. Structure, production and purification of the coil-tagged chimeric proteins used in this 
study. 
(A) Structure of CBD-Kcoil (1) and TRX-TEV-Ecoil-bFGF before (2) and after (3) cleavage by 
the TEV protease. 
(B) Recombinant proteins were analyzed by SDS PAGE under reducing condition and the gels 
were stained with Coomassie brilliant blue. CBD-Kcoil (1), TRX-TEV-Ecoil-bFGF (2) and 
Ecoil-bFGF (3). 
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 Ecoil-tagged growth factors can be recruited on gelatin through CBD-
Kcoil interactions. 
In order to test the bioactivity of the CBD-Kcoil chimeric protein, that is, its ability to bind 
simultaneously to gelatin and Ecoil peptide, various concentrations of CBD-Kcoil (1 to 1000 nM) 
were incubated in the wells of 96 well-CellBIND® plates that had been pre-coated with gelatin. 
After extensive washing to remove unbound CBD-Kcoil, Ecoil-bFGF or Ecoil-EGF were added at 
various concentrations and washed. Enzyme-linked immunosorbent assays (ELISA) against bFGF 
or EGF were performed to quantify the amount of bound GF, and thus the formation of a 
gelatin/CBD-Kcoil/Ecoil-GF ternary complex. As shown in Figure 4.3, Ecoil-bFGF and Ecoil-EGF 
were indeed recruited through coiled-coil interactions in a dose-dependent manner. Of salient 
interest, the non-specific binding of Ecoil-EGF and Ecoil-bFGF over gelatin was hardly detected 
by ELISA in the range of the concentrations we studied. 
The data were curve-fitted for the highest concentration of CBD-Kcoil (1000 nM) and led to a half-
maximum effective concentration (EC50) of 525 ± 25 pM, which is representative of the 
dissociation constant of the coiled-coil interaction between CBD-Kcoil and Ecoil-GF. This value 
is slightly higher than the previously reported values of KD for the interaction between Kcoil and 
Ecoil-EGF (KD = 185 pM)[221] possibly due to steric hindrance of the CBD moiety. 
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Figure 4.3. Tethering of Ecoil-bFGF (A) or Ecoil-EGF (C) on gelatin thanks to the CBD-Kcoil 
adaptor. 
For data corresponding to [CBD-Kcoil] = 1000 nM, EC50 values for the E/K coiled-coil 
interactions were determined by fitting the ELISA data corresponding to Ecoil-bFGF (B) and 
Ecoil-EGF (D). Values are given as mean value ± standard deviation (n = 2). 
 
 Stability of the gelatin/ CBD-Kcoil/Ecoil-GF complexes 
The interaction of CBD-Kcoil with gelatin was assessed by surface plasmon resonance (SPR). The 
protein was injected over a gelatin-coated chip at concentrations ranging from 10 to 100 nM. 
Control-corrected sensorgrams were indicative of a complex mode of binding as one can conclude 
from the visual inspection of their dissociation phase (Figure 4.4A). This deviation from a simple 
mode of interaction may be due to surface heterogeneity (that might have been favored by random 
gelatin immobilization via amine coupling procedure) or rebinding artefacts (e.g., if dissociated 
CBD-Kcoil was allowed to interact with immobilized gelatin rather than being eluted due to 
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diffusion limitations). The interactions were however well-fitted with a 1:1 stoichiometry model 
assuming a kinetically limiting CBD-Kcoil/gelatin complex rearrangement step after the initial 
interaction (two-step rearrangement model). This model was selected as it corresponds to a 1:1 
stoichiometry and as it is consistent with a cooperative mode of interaction due to the modular 
nature of CBD that contains six distinct domains all required for full affinity[53], [55]. This led to 
an apparent thermodynamic dissociation constant, KD, app of 3.2 nM, indicative of a strong collagen-
binding interaction. Similar results were obtained with an Ecoil-tagged CBD (data not shown), thus 
confirming that the Kcoil moiety did not participate to a large extent to gelatin binding. In 
comparison, native fibronectin has been reported to bind to type A gelatin with an apparent KD, app 
of 0.08 nM in an SPR assay[106]. This 40-fold difference in affinity is probably due to an avidity 
phenomenon, given the dimeric nature of native fibronectin. 
The stability of the gelatin/CBD-Kcoil/Ecoil-EGF complex was then assessed in an experimental 
design mimicking that of cell culture. More specifically, ELISA were conducted in gelatin-coated 
wells on which CBD-Kcoil and Ecoil-EGF had been added and left in PBS or PBS + 10% FBS for 
several days (with daily renewal of the medium) (Figure 4.4B). Since the thermodynamic 
dissociation constant of the coiled-coil interaction is lower than that of the collagen binding 
interaction, the observed decrease of the amount of tethered EGF is mostly due to the dissociation 
of the CBD domain from the gelatin substrate. In PBS, the complex displayed an initial release on 
the first 24h and then stabilized around 65% of its initial value, whereas in PBS + 10% FBS, the 
complex dissociated with a half-life of approximately two days. 
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Figure 4.4. Characterization of the stability of the gelatin/CBD-Kcoil complex. 
(A) Control-corrected SPR sensorgrams corresponding to the interaction of injected CBD-
Kcoil with immobilized gelatin.  
(B) ELISA against EGF was performed over gelatin-coated wells sequentially functionalized 
with CBD-Kcoil (300 nM) and Ecoil-EGF (10 nM). The wells were incubated either in PBS or 
PBS + 10 % FBS and the medium was changed every day. 
Values are given as mean value ± standard deviation (n = 2). 
 Bioactivity of Ecoil-bFGF 
HUVEC were cultivated in presence of either soluble Ecoil-bFGF or bFGF in the culture medium 
(1.1 pM to 3.5 nM) in a pristine CellBIND® plate. After four days of culture, the metabolic activity 
of the cells was assessed by a resazurin assay (Figure 4.5A). In solution, the Ecoil-tagged growth 
factor displayed a very similar behavior compared to native bFGF, with an EC50 close to 4 pM 
(equivalent to 0.07 ng/mL bFGF), a maximum of proliferation around 100 pM (equivalent to 1.7 
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ng/mL bFGF), followed by a decrease of its mitogenic activity at higher concentrations, in 
agreement with the literature[112], [113], [222]. 
Besides, the ability of Ecoil-bFGF being tethered via coiled-coil interactions to bind to its receptor 
was assessed by SPR. In the experiment shown in Figure 4.5B, 60 response units (RU) of Kcoil 
peptide were first immobilized on the SPR biosensor surface via a unique cysteine residue. 10 nM 
of Ecoil-bFGF were then injected on the Kcoil and mock surfaces to result in a 150 RU net 
accumulation (data not shown). The interaction between the Kcoil peptide and Ecoil-bFGF 
displayed a high affinity and stability, which is consistent with those we previously determined for 
the E/K coiled-coil interaction[27]. Afterwards, successive injections of FGFR1-Fc over 
immobilized Ecoil-bFGF unambiguously demonstrated that the captured growth factor was able to 
interact with its receptor ectodomain with high affinity (KD = 1.8 nM). For the sake of comparison, 
Lin et al. showed that the injection of FGF-2 over immobilized FGFR1-Fc displayed a dissociation 
constant of 99 nM[223]. The 55-fold difference in affinity is most likely due to the dimeric nature 
of FGFR1-Fc that induced an avidity phenomenon in our experimental design only, i.e. when the 
bivalent receptor was in solution. For Ecoil-EGF, we have already demonstrated it is able to bind 
to its receptor when tethered via coiled-coil interactions[22]. 
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Figure 4.5. Characterization of the bioactivity of Ecoil-bFGF. 
 (A) HUVEC metabolic activity measurements, after 4 days in 2% FBS medium. Values are 
given as mean value ± standard deviation (n ⩾ 3).  
(B) Control-corrected SPR sensorgrams corresponding to the interactions of injected FGFR1-
Fc with Ecoil-bFGF immobilized via coiled-coil interactions on a Kcoil-coated chip.  
 Tethered Ecoil-bFGF and Ecoil-EGF promote cell proliferation 
We then tested the ability of tethered Ecoil-bFGF to promote HUVEC proliferation. As can be seen 
in Figure 4.6A, as expected, CBD-Kcoil alone incubated at 300 nM on gelatin had no effect on 
HUVEC proliferation. In stark contrast, the addition of untagged or Ecoil-tagged bFGF (10 nM, 
followed by extensive washes) on pristine gelatin surfaces or on gelatin surfaces that had been 
incubated with CBD-Kcoil, resulted in a significant increase of cell growth, as deduced from the 
increase in metabolic activity (Figure 4.6A) and cell counts (data not shown). As a matter of fact, 
all of the conditions where bFGF or Ecoil-bFGF had been incubated over gelatin significantly 
promoted the proliferation of the cells, almost reaching the level of the positive control, that is, 
bFGF in solution (10 nM). These results highlight the fact that native bFGF naturally interacts with 
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collagen and in this case remains tethered on the gelatin layer after several washes, although it was 
hardly detected by ELISA (Figure 4.3). In an effort to dissect the differences in bFGF capture on 
gelatin, may it be through direct bFGF-gelatin interactions or via CBD-Kcoil, increasing 
concentrations of Ecoil-bFGF were incubated on gelatin that had been treated or not with 300 nM 
CBD-Kcoil. As can be seen in Figure 4.6B, the pre-incubation of CBD-Kcoil on gelatin reduced 
the proliferation of HUVEC for bFGF concentrations lower than 1 nM, when compared to Ecoil-
bFGF alone, suggesting that CBD-Kcoil competed with Ecoil-bFGF for gelatin binding (one would 
have expected comparable levels of cell proliferation at low Ecoil-bFGF concentrations if such was 
not the case). 
Of salient interest, the functionalization of gelatin with CBD-Kcoil (300 nM) and Ecoil-EGF (10 
nM) significantly improved the proliferation of HUVEC (Figure 4.6C) and promoted the survival 
of VSMC in serum-deprived conditions (Figure 4.6D), when compared to all the controls. The 
levels of proliferation (or survival) were equal or slightly higher than the positive controls, that is, 
EGF in solution (10 nM).   
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Figure 4.6. Bioactivity of Ecoil-bFGF and Ecoil-EGF tethered to collagen using a CBD-Kcoil 
adaptor. 
 (A) HUVEC metabolic activity measurements after 4 days in 2% FBS medium. Various 
combinations of proteins incubated over gelatin are presented. Soluble bFGF was used as 
positive control. 
(B) HUVEC metabolic activity measurements after 4 days in 2% FBS medium. Ecoil-bFGF was 
incubated at various concentrations over gelatin pre-functionalized or not with CBD-Kcoil 
(300 nM). 
(C) HUVEC metabolic activity measurements after 4 days in 2% FBS medium. Various 
combinations of proteins incubated over gelatin are presented. Soluble EGF was used as 
positive control. 
(D) VSMC metabolic activity measurements after 4 days in serum-free medium. Various 
combinations of proteins incubated over gelatin are presented. Soluble EGF was used as 
positive control. 
Values are given as mean value ± s.d. (n ⩾ 9). Statistical difference: n.s. stands for non-
significant, * stands for p < 0.05 and *** for p < 0.001. 
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4.6 Discussion 
A wide range of techniques have been developed for the tethering of growth factors to collagen 
scaffolds in order to provide a highly localized and long-lasting signaling. Among them, the 
random covalent grafting of growth factors has shown its potential[19], although in this case the 
bioactivity of the growth factors can be altered[23]. Another well-studied technique is the tethering 
of growth factors in a stable but non-covalent manner through specific affinity tags, such as biotin 
and streptavidin[26], coil peptides[29], DOPA-containing peptides[30] and heparin binding 
domains[31]. The use of chimeric proteins corresponding to growth factors fused to a collagen-
binding domain has been intensively studied since type I collagen is the most abundant protein in 
the human body[35], meaning that these recombinant proteins could bind collagen biomaterials as 
well as endogenous collagen. Hence, the in vivo bioavailability of these chimeric proteins is 
significantly improved, as their diffusion is reduced. 
We have here reported a system for the oriented capture of proteins over a gelatin or collagen 
substrate. The presented approach is versatile as it can be employed for the tethering of various 
kinds of proteins, in particular, we demonstrated that it perfectly suits the immobilization of growth 
factors. Moreover, this approach is modular as the use of an adaptor between the substrate (gelatin 
or collagen) and the protein (growth factors or other) provides several advantages. In particular, 
the strength of interaction between the protein and the substrate can be modulated by changing the 
affinity of the CBD moiety for the substrate. It is indeed possible to substitute the CBD of 
fibronectin for another CBD (for example the A3 domain of the von Willebrand Factor[67] or the 
CBD of the bacterial collagenase ColH[85]) or even a small collagen-binding peptide[14], without 
having to produce and purify other chimeric growth factors. Indeed, most growth factors are 
complex proteins that include several disulfide bridges and display a well-defined tertiary structure. 
It has already been established that the addition of a tag may negatively impact the bioactivity of 
the growth factor[22], therefore, modifying the adaptor removes all of the concerns about the 
bioactivity of the growth factor, synonym of an effort-intensive and time-consuming work. In the 
specific case of the E and K coils, the expression of numerous tagged chimeric proteins has been 
reported without any loss of bioactivity, such as growth factors (in particular EGF[22], VEGF[28] 
and bFGF, Figure 4.5A and 5B), the extracellular domains of various receptors (TGFβRII[220] and 
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TGFβIII[224]), and other proteins such as the alkaline phosphatase[225]. The specificity of the 
coiled-coil structure and the length of the coiled-coil complex appear to be key features resulting 
in an oriented tethering of growth factors at a sufficient (and possibly optimal) distance, which 
allows productive interactions with their cell-surface receptors. The affinity of the interaction 
between the growth factor and the substrate can also be modulated by varying the length[220] and 
the sequence of the coil peptide (Murschel et al. submitted) within the adaptor protein. Besides, 
this approach may also allow, if need be, the modification of the CBD adaptor chimera in order to 
add new functionalities, such as a recognition sequence for integrins in order to promote cell 
adhesion[226], [227]. 
The CBD we chose in this study is derived from human fibronectin (it includes all the modules 
from I6 to I9) and has an apparent affinity for gelatin of approximately 3 nM as determined by SPR 
(Figure 4.4A), which promotes its very stable attachment to gelatin-coated wells, with no release 
in PBS, and with a half-life of approximately 2 days in 10% FBS (Figure 4.4B). This is a direct 
consequence of the formation of a stable complex between gelatin and the CBD as observed in the 
dissociation phase of the SPR sensorgram, after an initial period of stabilization (Figure 4.4A). In 
combination with the very high affinity of the E/K coiled-coil interactions (ca. 500 pM, Figure 
4.3B and 3D), the system we designed appears to be suitable for cell culture over several days 
without adding exogenous soluble growth factors. Moreover, this system is flexible since it is 
possible to vary the density of tethered growth factors by changing the concentrations of CBD-
Kcoil and/or Ecoil-GF incubated (Figure 4.3A and 3C). This strategy of immobilization was 
successful in the case of EGF as a simple incubation of 10 nM of Ecoil-EGF allowed the capture 
of enough of this growth factor to get the same mitogenic and anti-apoptotic effects as those 
induced by 10 nM of soluble EGF renewed every other day (Figure 4.6C and 6D). These results 
are in accordance with what we observed for EGF tethered over other substrates on which Kcoil 
was immobilized in a covalent manner[29], [228]. Altogether, these results demonstrate the 
versatility and the endless possibilities of the coiled-coil system when combined with adaptor 
proteins, such as CBD. 
However, in the specific case of bFGF, our results indicate that the use of a tethering system 
through an affinity tag for the capture of bFGF over a gelatin or collagen matrix must be analyzed 
with caution since bFGF displays an intrinsic affinity for these materials[151]. Indeed, our data 
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indicate that the interaction between our adaptor protein (CBD-Kcoil) and gelatin may be in direct 
competition with the interaction between bFGF and gelatin (Figure 4.6B). We would like to draw 
the reader's attention to the fact that the interaction between bFGF and gelatin could not be 
highlighted with an ELISA assay, as presented in Figure 4.3A. More specifically, in absence of 
CBD-Kcoil, the observed response levels were significantly lower (5-fold difference) than in 
presence of this adaptor protein. The most probable explanation is that the antibody against bFGF 
that was employed in the ELISA interacted with the residues – or close to the residues – involved 
in the interactions with gelatin. This point is worth-mentioning since it may change the 
interpretation of previously published results presented by other research groups. More 
specifically, even if the design and the use of chimeric proteins of bFGF fused to a CBD has shown 
its usefulness (and more particularly in vivo[143], [149], [181]), the interpretation of the results 
requires to have performed the appropriate controls in all of the experiments, namely, comparing 
the effect of the chimeric  bFGF protein to those of pristine bFGF. We outline the fact that these 
controls are not systematically performed, probably due to negative results in ELISA assay[150], 
[226], [229]. 
4.7 Conclusion 
We have developed a versatile strategy for the grafting of growth factors on collagen-based 
materials that involve a collagen-binding adaptor and coiled-coil interactions. We showed that our 
approach enabled the capture of both EGF and bFGF in a highly bioactive and stable manner. The 
modular approach we undertook may make this strategy amenable to the development of more 
complex scaffolds combining several growth factors with collagen-based biomaterials and thus 
pave the way to the development of novel approaches in the field of tissue engineering for the 
reconstruction of complex tissues or organs. 
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CHAPITRE 5 DISCUSSION GÉNÉRALE 
 
Le concept d’immobiliser des biomolécules sur un biomatériau via un domaine de liaison au 
collagène est très prometteur (Chapitre 3) ; en plus des différents facteurs de croissances évoqués, 
d’autres entités ont déjà été attachées au collagène par des CBD, comme par exemple des anticorps 
dirigés contre des cellules cancéreuses[126], des protéines régulatrices du système 
immunitaire[100], des liposomes[230] ou même des nanoparticules afin d’imager le collagène in 
vivo[231]. La démarche consistant à créer un adaptateur moléculaire pour immobiliser n’importe 
quelle biomolécule permet la mise en place d’une plate-forme modulaire de fonctionnalisation 
du collagène. L’utilisation de l’interaction superhélice E/K, couplée à la très forte affinité du CBD 
de la fibronectine pour le collagène (KD = 3 nM), rend cette plate-forme particulièrement stable et 
adaptée à une fonctionnalisation sur plusieurs jours. En outre, l’interaction superhélice peut être 
facilement modulée en modifiant le nombre d’heptades[220] ou en introduisant des modifications 
dans la séquence des hélices alpha (Murschel et al., submitted). 
Par ailleurs, le développement de protéines de fusion comportant des étiquettes Ecoil est 
considérablement simplifié par rapport au développement de protéines fusionnées avec le CBD de 
la fibronectine, notamment à cause de la taille importante de ce dernier (39 kDa) et des nombreux 
ponts disulfures (12) qu’il contient. En particulier, il est raisonnable de penser que l’ajout de 
l’étiquette Ecoil (4 kDa) à ces protéines ne modifie pas substantiellement le rendement de 
production, ni la bioactivité de ces protéines chimères par rapport à leur forme native, que ce soit 
en cellules animales[22] ou en bactéries (Chapitre 4).  
En outre, la plate-forme de fonctionnalisation que nous avons développée est particulièrement 
simple d’utilisation, dans la mesure où il y a peu d’étapes et qu’elle ne prend que quelques heures. 
Il serait également envisageable de fonctionnaliser la surface de gélatine en une seule étape, où les 
facteurs de croissance étiquetées (Ecoil-GF) et l’adaptateur moléculaire (CBD-Kcoil) seraient pré-
mélangés, ce qui simplifierait encore le processus. Par ailleurs, il n’y a aucune réaction chimique, 
réactions qui nécessitent parfois des conditions opératoires difficiles (pH extrêmes ou solvant 
organique) ou des réactifs toxiques pour les cellules (glutaraldéhyde par exemple).  
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Les avantages liés à l’immobilisation de facteurs de croissance n’ayant aucune affinité pour le 
collagène sont très clairs, comme le démontrent les expériences menées avec Ecoil-EGF, qui 
confère à la surface des propriétés mitogéniques et anti-apoptotiques (Chapitre 4). Bien que ces 
avantages soient nettement moins évidents à observer dans le court terme avec les autres facteurs 
de croissances, comme c’est le cas pour Ecoil-bFGF, il est possible qu’une expérience sur une plus 
longue période et/ou dans un milieu de culture plus concentré en sérum ait montré une différence 
significative. En effet, l’interaction non-spécifique entre le bFGF et la gélatine est probablement 
moins stable que l’interaction de liaison au collagène du CBD. Cette hypothèse trouve echo dans 
les résultats des expériences de fonctionnalisation de biomatériaux en collagène avec des protéines 
chimères de la forme CBD-bFGF (Chapitre 3), et qui induisent un effet bénéfique par rapport au 
bFGF natif. 
Il est clair que la stratégie développée dans les travaux de recherche exposés ici demanderait un 
certain effort pour passer à l’étape clinique, notamment du fait qu’elle implique plusieurs protéines 
non naturelles, qui doivent chacune prouver leur innocuité. Cependant, certaines protéines de 
fusion sont déjà autorisées par les autorités de régulation dans le cas d’applications bien précises, 
comme par exemple la fusion entre le facteur de coagulation VIII et le fragment Fc (d’un anticorps) 
ou encore entre le facteur IX et l’albumine, ce qui tend à prouver que ce n’est pas impossible.  
L’idée sous-jacente à la fonctionnalisation de surface est, avant tout, de stimuler les cellules de 
l’hôte pour induire une réponse biologique : elle est donc potentiellement beaucoup plus simple à 
mettre en œuvre (voire plus économique) que n’importe quelle stratégie de délivrance cellulaire, 
qui implique d’avoir une certaine compatibilité, notamment au niveau du complexe majeur 
d’histocompatibilité. Par ailleurs, le risque d’induire un cancer par cette méthode est faible, en 
particulier lorsque peu de facteurs de croissance sont utilisés, par exemple dans le cadre d’une 
fonctionnalisation stable. Cependant, il est tout à fait imaginable à moyen terme de combiner ces 
deux approches, avec des cellules spécifiques incluses dans un biomatériau à base de collagène, 
lui-même fonctionnalisé pour promouvoir la survie ou la prolifération de ces cellules. Un bel 
exemple serait l’implantation de précurseur neuronaux pour le traitemet de maladies dégénératives 
comme la maladie de Parkinson. 
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CHAPITRE 6 CONCLUSION ET RECOMMANDATIONS 
 
Les travaux de recherche présentés ont contribué à l’avancement des connaissances dans le 
domaine de la médecine régénératrice d’une part grâce à la publication de l’article de revue, qui 
compile l’ensemble des travaux effectués dans le domaine des CBD. En effet, aucune revue de 
littérature publiée ne détaillait jusque-là l’ensemble de la famille des CBD en les caractérisant et 
en répertoriant les différentes protéines de fusion déjà construites. 
D’autre part, nous avons pu mettre en place et caractériser de manière poussée les propriétés 
biophysiques d’une plateforme de fonctionnalisation de la gélatine à l’aide de l’interaction 
superhélice « coiled-coil ». Une telle caractérisation permet non seulement de mieux comprendre 
1) l’interaction entre le CBD et la gélatine et 2) l’interaction superhélice entre deux protéines de 
fusion, mais également 3) l’interaction entre les facteurs de croissance et la gélatine. 
Cette stratégie de fonctionnalisation pourrait à l’avenir être améliorée en analysant les différences 
qu’il peut exister entre un substrat en collagène et en gélatine, ou encore entre un substrat en 2D et 
en 3D (une éponge de collagène par exemple). Par ailleurs, d’autres facteurs de croissance 
pourraient être testés, comme Ecoil-VEGF qui est une protéine dimère (bien que le VEGF natif se 
lie probablement déjà au collagène) ou d’autres biomolécules étiquetées avec Ecoil, comme des 
anticorps. 
Le CBD de la fibronectine a été choisi car il possède une forte affinité pour le collagène, cependant, 
il est envisageable d’étudier d’autres CBD pour moduler cette interaction. Par exemple, des 
répétitions successives de peptides se liant au collagène (comme TKKTLRT) pourraient faire 
preuve d’une affinité comparable, (voire supérieure grâce au phénomène d’avidité), mais avec une 
taille plus modeste. 
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